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I. INTRODUCTION 
Cancer is one of the biggest health problems in our days and led to 
14.1 million new cancer cases and 8.2 million cancer related deaths 
worldwide in 2012. The leading cause of cancer in males worldwide is lung 
cancer, followed by prostate and colorectal cancer. In females, breast 
cancer is the most frequently diagnosed form of cancer, followed by 
colorectal cancer and lung cancer [1]. Lung cancer causes the most cancer 
related deaths in males followed by liver cancer, whereas breast cancer is 
the major cause of cancer related deaths in females. Estimations of the 
American Cancer Society predict 21.7 million new cancer cases and 
13 million cancer related deaths in 2030 due to growth and aging of the 
population and different other risk factors [1, 2]. These risk factors are 
omnipresent in our societies and are frequently increasing. According to the 
American Cancer Society, lung cancer is primarily caused by tobacco 
smoking and air pollution. Therefore, lung cancer could be prevented 
effectively by tobacco control and campaigns against smoking [1]. A further 
risk factor for various cancers like colon cancer or post-menopausal breast 
cancer could be detected in an excess body mass index and overweight [3]. 
Moreover, malnutrition with consuming large amounts of red and processed 
meat can increase the risk of developing for instance colorectal and lung 
cancer [4]. An increased alcohol intake, virus infections with hepatitis B and 
C virus, tobacco smoking and aflatoxin uptake are common risk factors for 
developing liver cancer [5, 6]. Also altered reproductive patterns can have 
influence on cancer development both in women and in children. Moreover, 
recent use of oral contraceptives slightly increases the risk of developing 
breast cancer in females [7]. At the same time, the risk to develop acute 
lymphoblastic leukemia in children is increased with older parental age [8]. 
  
The five-year survival in patients between 15 and 74 years diagnosed with 
liver cancer amounts 17%, 61% for leukemia, and 88% for breast cancer in 
females in Germany [9]. These survival rates combined with the expected 
increasing cancer cases in the future and omnipresent risk factors elucidate 
that novel cancer therapeutics are required.        
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Procedures taking place in humans or animals are hardly to imitate in cell 
culture or in vitro setups. Pharmacokinetics, i.e. resorption, distribution, 
metabolism and excretion have an important influence on a compound`s 
mode of action in animal models [10]. Furthermore, insights in efficacy and 
toxicity are gained by animal models in an early state of developing a 
compound. Finally, in vivo models can serve as an important source of 
information between in vitro testing and clinical application, but always being 
aware of animal experiments` limitations relating to their translation to 
clinical practice. Today, animal experiments represent the major preclinical 
tool of evaluating the potential of therapeutic cancer drugs. Therefore, in 
vivo models still remain a unique source of in vivo information, besides 
emerging translational alternatives [11]. Finally, even critical scientists 
support that “animal models can and have provided many crucial insights 
that have led to major advances in medicine” [12].  
The aim of our lab is to contribute to finding new cancer therapeutics. 
Therefore, we use promising novel compounds and test them on their   
anticancer potential. Natural and sometimes synthetic compounds are 
tested on different tumor cell lines, patient derived xenograft cells or patient 
cells in vitro. In this project, the most promising of these compounds are 
tested in vivo as a further step of characterizing their potential. 
1. Animal experiments in cancer research 
According to the “Bundesministerium für Ernährung und Landwirtschaft” 
(BMEL) 2,753,051 laboratory animals were used for research purposes in 
Germany in 2015. 58.7% of all laboratory animals were used for basic 
research purposes, containing 6.7% for oncology research. Furthermore, 
13.6% of all laboratory animals were used for translational and applied 
research purposes, containing 33.9% research on oncologic diseases. The 
biggest group of laboratory animals was represented by 2,005,097 mice 
[13]. Advantages of mice are their small size and therefore their 
uncomplicated maintenance. Moreover, they have high reproduction rates, 
a short life span and large litters [14, 15].               
In terms of oncology research, there are different ways to classify murine 
cancer models. The first point to schedule tumor models are ectopic and 
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orthotopic models. Solid tumors can be generated by injecting tumor cells 
of different origin subcutaneously which is an often-used ectopic tumor 
model. Tumor cells injected directly into the organ they physiologically 
appear, like for example the mammary fat pad for breast cancer cells or the 
liver for hepatocellular carcinoma, create an orthotopic tumor model [16, 
17]. By injecting tumor cells into the bloodstream an assay of colony 
formation, also called dissemination assay can be conducted. Moreover, it 
can be differentiated between syngeneic and xenograft transplantations of 
tumor cells. While syngeneic models work with tumor cells and mice with an 
identical genetic background, xenograft models combine cancer cells of one 
species (e.g. human cancer cells) with immunocompromised mice. In 
syngeneic tumor models, mice with an intact immune system are used, so 
the influence of the immune system on tumors can be considered [16]. In 
contrast the benefit of xenograft models is the closer relation to human 
patients, but as these mice are immunocompromised, the role of the 
immune system is reduced [18]. Highly immunocompromised mice are often 
used as humanized mouse models for tumors of the hematopoietic system 
and for research with patient-derived xenograft cells [19, 20]. As the mouse 
genome was completely sequenced in 2002, genetical manipulations are 
also conducted in mice [21].  Besides of injecting cancer cells into mice to 
create a tumor, research on transgenic mouse models is done to get 
insights in genes responsible for cancer formation. By genetic modification 
of these genes, it is also possible that mice develop tumors spontaneously 
and therefore represent a better model of human cancer patients [18]. To 
evaluate novel chemotherapeutics also genetically altered mice are used to 
predict chemotherapy response in human patients [22].          
According to the German animal welfare act, animals have to be alimented, 
maintained, and housed suitable to their species [23]. Therefore, 
interactions with laboratory animals and use of them always has to be based 
on ethical and humane standards and is protected by the German animal 
protection law.                    
In this thesis, different murine tumor models were used to investigate the 
potential of natural and synthetic compounds against cancer cells in vivo. 
These tumor models give the opportunity to evaluate variable modes of 
action a compound showed in vitro before, as e.g. inhibition of tumor cell 
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proliferation, inhibition of metastasis formation, or inhibition of tumor cell 
migration, in vivo.            
Tumor dissemination assays are often used as a first step of in vivo 
characterization of compounds, which showed promising effects on tumor 
cell migration and invasion in vitro. Thus, dissemination assays show if a 
compound has general influence on tumor formation in vivo.  
 
Figure 1: Tumor dissemination model 
 
In ectopic tumor models, the influence on tumor proliferation and tumor 
growth of a compound can be evaluated via measurements with a digital 
caliper or bioluminescence imaging using the IVIS® spectrum. 
 
Figure 2: Ectopic tumor model 
 
In a leukemia model the situation of leukemic tumor burden distributed in 
the whole body is mimicked to test compounds on their efficiency to reduce 
the number of leukemic tumor cells in an organism. The leukemic tumor 
burden is measured via bioluminescence of the tumor cells with the IVIS® 
spectrum.  
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Figure 3: Leukemia model 
 
An intrahepatic metastasis model offers the chance to investigate 
metastasis formation of liver cancer cells from the spleen to the liver. In this 
orthotopic tumor model compounds with promising effects against tumor cell 
metastasis can be evaluated in vivo. 
 
Figure 4: Intrahepatic metastasis model. A) Cell injection into the spleen. 
B) Metastasis formation. Figure created by Prof. Dr. Johanna Pachmayr 
(Paracelsus Medical University, Austria). 
 
 
I. Introduction     6 
2. Problems in cancer treatment 
Common cancer treatment in human patients consists of a variable 
combination of surgery, chemotherapy, radiation, and immunotherapy [24]. 
As the aim in cancer treatment in human medicine is often a curative therapy 
and therefore associated with high dosages of chemotherapeutic agents or 
radiation, different wearing and stressful side effects can occur during and 
after the treatment [25]. Besides the anesthetic risk that is attended by 
surgical interventions, amputation of the affected part of the body such as 
the breast via mastectomy can lead to depression in many cases [26]. 
Concerning immunotherapy with monoclonal antibodies, side effects as 
acute anaphylactic reactions, cardiotoxicity, and gastrointestinal 
perforations can occur as reviewed by Hansel et al. [27]. Radiation therapy 
can lead to local or loco-regional side effects, which can become manifest 
within a few weeks after the treatment, like erythema and desquamation of 
the skin or nausea. Late effects of radiation therapy can appear up to years 
after the treatment, represented by radiation-induced fibrosis, neural 
damage, and even radiation-induced malignancies [25]. Chemotherapeutic 
treatment mainly causes systemic side effects as emesis, nausea, and hair 
loss [28]. A further problem concerning chemotherapy is the development 
of drug resistance in cancer cells. In metastatic cancer, drug resistance is 
believed to cause more than 90% of treatment failure in human patients [29]. 
This drug resistance can be of intrinsic or acquired origin, with molecular 
resistance mechanisms as e.g. increased drug efflux, decreased drug influx, 
drug inactivation, alteration in drug targets, and evasion of apoptosis [29, 
30]. To overcome chemo-resistance and sensitize cancer cells to treatment 
with chemotherapeutic drugs, as well as to find options in cancer treatment 
without severe side effects, new chemotherapeutic drugs are investigated 
in our lab. These new compounds were tested in combination with approved 
chemotherapeutic drugs to improve their effects or tested on their single 
treatment potential in vivo.  
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3. Compounds for in vivo experiments 
Natural and synthetic compounds as well as approved drugs were tested in 
our lab to discover new options for anticancer therapy. In our lab 
compounds were tested in vitro on their anti-cancer activity. In this project 
the most promising of these compounds were tested in vivo to investigate 
their potential in a mammalian. In the cell, these compounds react on 
several important targets, which are still unknown for some of the tested 
compounds. On the one hand our compounds can be applied as novel 
drugs for cancer treatment. On the other hand, they represent important 
tools for target identification.  
3.1. Natural compounds 
The group of natural compounds consists of compounds and products from 
plants, microbes, and animals [31]. They can be subdivided in unaltered 
natural products, botanical drugs, biological macromolecules, and natural 
product derivatives [32]. Natural products are characterized by a high 
diversity of chemical structures and biological attributes [33]. They play an 
important role in the chemotherapy of cancer and are used for their anti-
infective functions [31, 33]. Difficulties in access and supply and an often 
effortful product chemistry of natural products are major problems in natural 
product research [31]. A solution for this can be found in developing 
fragments of natural products with a reduced structural complexity. Their 
chemical synthesis needs less steps, but results in a similar or even higher 
potent compound [34]. Natural compounds are the origin of a multitude of 
active ingredients in medicines [31, 33]. Of the between 1981 and 2014 
newly approved drugs, 42% had their origin in natural products, containing 
4% unaltered natural products. Moreover, 52% of all drugs with anticancer 
effects approved within this period had their source in natural products [32]. 
These data elucidate that natural compounds are an important source for 
novel therapeutics and offer new treatment options for various diseases. So 
far unknown compounds which showed promising effects in vitro in our lab 
were evaluated in mouse models to proof their capability in vivo in this 
project. 
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3.1.1. Neocarzilin A 
Neocarzilin A belongs to a group of chlorinated polyenones named 
neocarzilins. In addition to neocarzilin A also neocarzilin B and C are 
members of these polyenones isolated by the myxobacterium Streptomyces 
carzinostaticus var. F-41 [35, 36]. Streptomyces carzinostaticus also 
produces neocarzinostatin, which shows antitumoral activities in vitro and 
in vivo [37]. Neocarzilin A itself has high potent activity against K562 chronic 
myelogenous leukemia with IC50 values of 0.06 µg/ml in vitro [36]. Moreover, 
an acute toxicity in Institute of Cancer Research (ICR) mice is known with 
LD50 values of 88.1 mg/kg. Moreover, chemical synthesis of neocarzilin A is 
possible with L-isoleucine as first reactant [38]. In our lab neocarzilin A 
showed promising antiproliferative and anti-metastatic effects against 
various tumor cell lines in vitro. Furthermore, there is first evidence that 
neocarzilin A interacts with the synaptic vesicle membrane protein VAT-1 
(unpublished data). 
 
Figure 5: Chemical structure of neocarzilin A [35] 
 
3.1.2. CA1 
The pseudonym CA1 is used for a natural compound due to pending patent 
application.  CA1 is known for its antibacterial effects and approved for the 
treatment of various infections. In vivo mouse models showed that CA1 is 
active against different tumor cells as well as sensitizes cancer cells to 
chemotherapy.  
 
3.1.3. Jasplakinolide 
Jasplakinolide is a natural compound isolated from the marine sponge 
Jaspis johnstoni [39]. Its mode of action consists of inducing actin 
polymerization and stabilizing actin filaments [40]. As reviewed by Allingham 
et al. the ratio between monomeric and filamentous actin in the cell can be 
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regulated and influenced by different proteins. Due to its filaments, actin 
plays an important role in locomotion, division and growth of cells [41]. In 
the beginning, jasplakinolide was investigated because of its antifungal 
activity against Candida species [42]. In terms of cancer it shows 
antiproliferative effects on human prostate carcinoma cells in vitro [43]. In 
vivo, jasplakinolide shows antitumor effects in mouse xenograft 
experiments on prostate carcinoma and Lewis lung carcinoma, also working 
as a radiation sensitizer [44]. Application in mice is reported via 
subcutaneous and intraperitoneal injection, subcutaneous continuous 
infusion as well as oral administration. Mortal toxicity is reached with a single 
4 mg/kg subcutaneous injection, whereas 1.5 mg/kg administered twice 
daily via intraperitoneal injection can be tolerated for one week [42, 44]. 
Jasplakinolide was also tested in zebrafish and did not cause acute toxicity 
in 0.5 µM concentration [45]. These in vivo data indicate that actin inhibitors 
show toxic properties even in low concentrations leading to challenges in 
adequate dosing.  
 
Figure 6: Chemical structure of jasplakinolide [42] 
 
3.1.4. Latrunculin B 
The natural compound latrunculin B is purified from red sea sponge 
Negombata magnifica (formerly Latrunculia magnifica) [46]. Negombata 
magnifica produces also a second natural toxin named latrunculin A with 
similar effects as latrunculin B in vitro [47]. Latrunculins build a complex with 
G-actin and therefore disturb actin filament organization [47, 48]. 
Furthermore latrunculin B has a stabilizing effect on G-actin and inhibits shift 
from G-actin into F-actin [46]. Latrunculins influence the actin organization 
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and cell morphology in mouse neuroblastoma cells and hamster fibroblast 
cells [47, 49]. In vivo, latrunculin A shows antitumor effects in peritoneal 
dissemination assays against human gastric cancer cell lines [50].  
 
Figure 7: Chemical structure of latrunculin B [49] 
 
3.2. Synthetic compounds 
Synthetic compounds represent another important group of compounds in 
development of pharmaceuticals with anticancer activities. Today, chemical 
libraries with improving quality can be screened for one million compounds 
in a few months [51]. Screening properties are for example 3D-shape and 
electrostatic attributes [52]. Synthetic compounds tested in vitro in our lab 
with promising anticancer effects were tested in vivo afterwards in this 
project. 
3.2.1. Ned-19 
Ned-19 was found by screening a chemical library (ZINC) for compounds to 
do research on NAADP signaling [52]. Ned-19 works as a noncompetitive 
antagonist for NAADP and inhibits NAADP signaling in sea urchin eggs and 
in mammalian cells [52]. As NAADP is a potent second messenger for Ca2+ 
release, Ned-19 is able to inhibit Ca2+ release [53, 54]. NAADP also 
activates two-pore channels (TPCs), which are Ca2+ permeable cation 
channels in the endolysosomal system of cells. TPCs play an important role 
in the regulation of the endocytic transport and therefore have an influence 
on integrin trafficking in a cell [55]. As elucidated in nature reviews, integrins 
are important for cell migration and hence for tumor metastasis [56]. 
Therefore, Ned-19 is able to reduce tumor cell migration in melanoma cells 
I. Introduction     11 
in vitro. Moreover, Ned-19 has a reducing influence on tumor metastasis, 
tumor vascularization, and tumor growth in vivo [57]. Furthermore, Ned-19 
inhibits platelet aggregation and secretion, as well as whole-blood 
aggregation [54]. In vivo, mice tolerate Ned-19 i.p. injections every second 
day with a dose of 5 mg/kg over four weeks [57].  
 
Figure 8: Chemical structure of Ned-19 [58] 
 
3.2.2. PS89 
The small molecule PS89 belongs to the compound class T8 which was 
identified as a promising candidate for chemo-sensitization by screening of 
a commercial compound library. In combination with the chemotherapeutic 
drug etoposide, PS89 sensitizes cancer cells towards chemotherapy and 
therefore leads to an increased apoptosis in vitro [59]. PS89 works as a 
reversible and specific protein disulfide isomerase (PDI) inhibitor and in this 
way is able to influence the unfolded protein response [60]. In comparison 
to original T8 an azid group replaces a fluorine in PS89 and therefore PS89 
perfectly fits into the binding grooves of PDI. Thus, PS89 has the best 
sensitizing effects on etoposide treatment of the T8 family in vitro [59]. 
 
Figure 9: Chemical structure of PS89 [59] 
 
3.2.3. Dinaciclib 
Dinaciclib (SCH 727965) was identified by an in vivo screening system in 
search of CDK inhibitors which combine “potency, pharmacokinetic, 
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efficacy, and safety parameters” [61]. In vitro, dinaciclib inhibits CDK1, 
CDK2, CK5, and CKD9 with IC50 values between 1 and 4 nmol/l. Compared 
with flavopiridol, another well-known CDK inhibitor, the inhibition of CDK1 
and CDK9 by dinaciclib is similar but the inhibition of CDK2 and CDK5 is 
12-fold and 14-fold stronger, respectively [62]. Dinaciclib also has inhibitory 
effects on the unfolded protein response by interrupting the IRE1 (inositol-
requiring enzyme 1) arm [63]. It is known that short dinaciclib treatment 
causes long running effects in vitro. Moreover, dinaciclib shows antitumoral 
effects against a multitude of different human tumor cell lines in vitro. The 
MTD for seven days daily intraperitoneal injection is higher than 60 mg/kg, 
the MED is 5 mg/kg in nude mice [62]. Antitumor effects are reported 
against ovarian cancer [62],  triple negative breast cancer in a PDX model 
[64], acute myeloid leukemia [65], human melanoma [66], and human 
pancreatic cancer [67] in vivo. Dinaciclib was also tested in phase II clinical 
studies for acute myeloid leukemia [68], non-small cell lung cancer [69], and 
advanced breast cancer [70]. Since 2011 dinaciclib is granted orphan 
designation for the treatment of chronic lymphocytic leukemia [71]. 
 
Figure 10: Chemical structure of dinaciclib [62] 
 
3.2.4. Sorafenib 
Sorafenib (BAY  43-9006) is an oral multikinase inhibitor, which is approved 
as Nexavar®. Bayer and Onyx identified through high-throughput screening 
for Raf1 kinase inhibitors 3-thienyl urea as a promising compound and 
chemically modified it with sorafenib as result. Sorafenib inhibits receptor 
tyrosine kinase signaling and activation of Raf. This leads to apoptosis, 
inhibition of metastasis formation, as well as inhibition of cell proliferation 
and neovascularization as reviewed by Wilhelm et al. [72]. Antitumor effects 
are shown in different in vivo experiments, for example in xenograft models 
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of human colon cancer, non-small cell lung cancer, and breast cancer [73]. 
Efficacy against tumors is also shown in xenograft tumor models of 
malignant melanoma [74], differentiated thyroid carcinoma (DTC) [75], 
renal-cell carcinoma (RCC) [76], and hepatocellular carcinoma (HCC) [77]. 
In mice, sorafenib is administered orally or via intraperitoneal injection in 
doses up to 100 mg/kg daily or twice a day [73, 74]. Sorafenib was tested 
in phase III clinical trial for RCC [78], HCC [79-81], and DTC [82]. In patients 
with advanced HCC, sorafenib prolongs median overall survival for about 
three months in comparison to placebo [79, 81]. In humans, 400 mg 
sorafenib is administered twice daily by oral treatment [79]. According to the 
European Medicines Agency, Nexavar® is approved as first line therapy 
against HCC and second line therapy against RCC and DTC [83]. Moreover, 
Nexavar® is the only approved drug for treating advanced HCC [84].  
 
Figure 11: Chemical structure of sorafenib [85] 
 
3.3. Compounds for combination therapy 
Clinical approved compounds might be enhanced by the combination with 
an experimental compound. Our experimental compounds were tested on 
their chemo-sensitizing effects to improve the therapeutic effects of 
approved drugs. Therefore, daunorubicin and doxorubicin, two long known 
chemotherapeutics, were combined with experimental compounds. 
Expectable effects after promising in vitro testing of these combinations 
might be synergistic or additive antitumoral effects.  
3.3.1. Daunorubicin 
The anthracycline antibiotic daunorubicin is a natural product of 
Streptomyces peucetius var. caesius [86]. The main mechanisms of 
function are DNA intercalation, generation of free radicals, and inhibition of 
topoisomerase II, which leads to DNA strand breaks, as summed up by 
Gewirtz et al. [87]. Daunorubicin is administered in dose of 60 mg/m2 in 
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human patients [88].  Daunorubicin hydrochloride is approved for 
combination treatment of acute myeloid leukemia and acute lymphatic 
leukemia in children and adults [89]. In vivo mouse models show that 
liposomal daunorubicin (DaunoXome®) increases steadily in the tumor, 
whereas free daunorubicin shows a peak level in short time after the 
injection. Moreover, liposomal daunorubicin is more specific to tumor tissue 
than free daunorubicin [90]. Therapeutic efficacy of liposomal formulation of 
daunorubicin is increased in comparison to free daunorubicin in vivo [91]. In 
phase III clinical trial liposomal daunorubicin reduces late relapses and 
therefore is considered to improve overall survival and disease-free 
intervals [92]. Liposomal daunorubicin has orphan disease designation for 
the treatment of acute myeloid leukemia [93].  
 
Figure 12: Chemical structure of daunorubicin [94] 
 
3.3.2. Doxorubicin 
Doxorubicin also belongs to the group of anthracycline antibiotics and is 
produced by Streptomyces peucetius var. caesius [86]. Its mode of action 
consists on DNA intercalation, covalent binding to DNA, inhibition of the 
topoisomerase II and therefore stabilization of the cleavage complex. 
Doxorubicin also produces free radicals by redox cycling. These free 
radicals cause cardiotoxic effects of doxorubicin, which leads to a restriction 
in dose frequency. It also causes acute bone marrow toxicity, which leads 
to a reduced dose intensity, as reviewed by Cummings et al. [95]. 
Furthermore, doxorubicin causes myopathy in cardiac muscle cells in vitro 
and in vivo by a decrease of muscle specific genes [96]. To circumvent 
negative side effects of doxorubicin, polyethylene glycol (PEG)-liposomal 
doxorubicin is a new option to use doxorubicin. PEG-liposomal doxorubicin 
has different pharmacokinetic characteristics as well as a longer circulation 
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time in the blood and an increased accumulation in tumors, as reviewed by 
Sharpe et al. [97]. In vivo, liposomal doxorubicin shows a higher residence 
time as free doxorubicin. Moreover, it has a stronger effect on tumor growth 
inhibition. Mice treated with liposomal doxorubicin show a constant body 
weight, compared with a decreasing body weight of mice treated with free 
doxorubicin. Free doxorubicin causes higher peak plasma concentrations 
after intratumoral injection, which can lead to acute cardiac toxicity [98]. 
According to the European Medicines Agency, liposomal doxorubicin 
hydrochloride (Caelyx®) is approved for breast neoplasm, multiple 
myeloma, ovarian neoplasm, and Kaposi`s sarcoma [99].  
 
Figure 13: Chemical structure of doxorubicin [100] 
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4. Aim of the thesis 
The aim of the thesis was the in vivo evaluation of promising compounds 
concerning their antitumor activity to find out novel therapeutic options 
against cancer. Compounds which showed potent anticancer effects in vitro 
were selected for testing in suitable mouse models. In the first part of the 
thesis the aim was to find out appropriate dosages of compounds which did 
not have negative effects on the general condition of the mice. In the second 
part we aimed to characterize compounds in more detail by elucidating their 
pharmacokinetic profile. In the main part of the thesis the influence of 
different compounds on tumor cell dissemination, tumor growth, and tumor 
metastasis was investigated. In tumor dissemination models the impact of 
compounds and cellular mechanisms on cell distribution after intravenous 
injection was tested. In subcutaneous tumor models the growth of different 
tumor cell lines was described. Moreover, the effects of compounds on 
tumor growth were tested with subcutaneous tumor models as well as with 
an intravenous leukemia model. Furthermore, the influence of compounds 
on tumor metastasis was tested in an intrahepatic metastasis model, which 
was conducted for the first time in our working group. Whenever possible, 
tumor load was detected by measurement of bioluminescence signals of 
tumor cells via the IVIS® spectrum. It was part of the thesis to create 
experimental setups, find suitable mouse models, plan in vivo experiments 
always considering animal welfare and legislation of animal protection, to 
perform the experiments, and to analyze the obtained data.  
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II.  MATERIALS, MICE, AND METHODS 
1. Materials 
1.1. Compounds 
DaunoXome® kindly provided by Prof. Dr. Irmela Jeremias 
(Helmholtz Center Munich, Germany) 
Dinaciclib   Selleckchem (Munich, Germany) 
Doxorubicin Sigma Aldrich Chemie GmbH (Steinheim, 
Germany) 
Jasplakinolide  Bioz (Palo Alto, USA) 
Latrunculin B Sigma Aldrich Chemie GmbH (Steinheim, 
Germany) 
Ned-19   Tocris Bioscience (Bristol, United Kingdom) 
Neocarzilin A  Prof. Stephan Sieber (TUM Munich, Germany) 
PS89 Prof. Uli Kazmaier (University of Saarland, 
Germany) 
Sorafenib   Enzo Life Sciences GmbH (Lörrach, Germany) 
1.2. Cells 
AML-372 kindly provided by Prof. Dr. Irmela Jeremias 
(Helmholtz Center Munich, Germany) 
Hep55c-luc cells kindly provided by Dr. Lars König (LMU Munich, 
Germany) 
HUH7 wt cells Japanese Collection of Research Bioresources 
(Osaka, Japan) 
HUH7 resi(+) cells generated by Maximilian Ardelt (LMU Munich, 
Germany) 
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HUH7 resi(+)-luc cells luciferase transfected by Martina Meßner (LMU 
Munich, Germany) 
HUH7 resi(-) cells generated by Martina Meßner (LMU Munich, 
Germany) 
McA-RH7777 cells kindly provided by PD Dr. Hans Zischka 
(Helmholtz Centre Munich, Germany) 
Ril175-luc cells kindly provided by Dr. Lars König (LMU Munich, 
Germany) 
Ril175-luc Cdk5 KO cells generated by Maximilian Ardelt (LMU Munich, 
Germany) 
Ril175-luc TPC2 KO cells generated by Martin Müller (LMU Munich, 
Germany) 
4T1-luc cells   Perkin Elmer (Rodgau, Germany) 
4T1-luc siTPC2 cells transfected by Dr. Ong Nam Phuong Nguyen 
(LMU Munich, Germany) 
4T1-luc siNT cells transfected by Dr. Ong Nam Phuong Nguyen 
(LMU Munich, Germany) 
1.3. Cell culture 
Cell culture flasks  Sarstedt AG & Co. (Nümbrecht, Germany) 
Fetal calve serum  Biochrom AG (Berlin, Germany) 
DD medium   provided by Prof. Dr. Irmela Jeremias 
DMEM medium  PAA Laboratories (Pasching, Austria)  
DMSO Sigma Aldrich Chemie GmbH (Steinheim, 
Germany) 
EDTA Carl Roth GmbH und Co. KG (Karlsruhe, 
Germany) 
Kolliphor EL® (solutol) Sigma Aldrich Chemie GmbH (Steinheim, 
Germany) 
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PBS (ph 7.4) 132.2 mM NaCl + 10.4 mM Na2HPO4 + 
3.2 mM KH2PO4 + H2o 
RPMI 1640 medium Pan-Biotech GmbH (Aidenbach, Germany) 
Trypsin Pan-Biotech GmbH (Aidenbach, Germany) 
Trypsin/EDTA                    Trypsin 0.05%, EDTA 0.20%, PBS  
1.4. In vivo experiments 
Anexate®   Cheplapharm (Mesekenhagen, Germany) 
Antisedan®   Vetoquinol (Ismaning, Germany) 
Bepanthen® Augensalbe   Bayer Vital GmbH (Leverkusen, Germany) 
Betaisodona® Lösung        Mundipharma GmbH (Limburg, Germany) 
Buprenovet®   Bayer AG (Leverkusen, Germany) 
BD Micro-FineTM 0.3 ml BD Medical (Le Pont de Claix, France) 
Cotton swabs Heinz Herenz Medizinalbedarf GmbH 
(Hamburg, Germany) 
Cutasept®  
Hautdesinfektion                Paul Hartmann AG (Heidenheim, Germany) 
D-Luciferin (sodium salt) Biomol GmbH (Hamburg, Germany)  
Dorbene®   Zoetis (Berlin, Germany) 
Dormicum®   La Roche (Basel, Switzerland) 
EDTA blood tubes  Sarstedt AG & Co. (Nümbrecht, Germany) 
Ethanol 70% Brenntag GmbH (Mühlheim an der Ruhr, 
Germany) 
Hamilton syringe  Sigma-Aldrich (Taufkirchen, Germany) 
Isofluran CP   CP-Pharma® (Burgdorf, Germany) 
Needles   Terumo (Eschborn, Germany) 
Paraformaldehyde  AppliChem (Darmstadt, Germany) 
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Restrainer   Agnthos (Lidingö, Sweden) 
SurgiproTM Monofilament  
Polypropylene 5-0  Covidien (Dublin, Ireland) 
Syringes                             Henry Schein VET GmbH (Hamburg, Germany) 
1.4.1. Environmental enrichment 
Aspen bricks   Plexx B.V. (Elst, The Netherlands) 
Arbocel Crinklets Natural J. Rettenmaier & Söhne GmbH und Co. KG 
(Rosenberg, Germany)  
Fast-Trac®    Plexx B.V. (Elst, The Netherlands) 
Fruit Crunchies  Plexx B.V. (Elst, The Netherlands) 
Litter    Plexx B.V. (Elst, The Netherlands) 
Mouse igloo   Plexx B.V. (Elst, The Netherlands) 
Mouse tunnel  Plexx B.V. (Elst, The Netherlands) 
Nestlets   Plexx B.V. (Elst, The Netherlands) 
Wire hanger   Plexx B.V. (Elst, The Netherlands) 
1.7 Instruments 
Canon EOS 450D  Canon Deutschland GmbH (Krefeld, Germany) 
Centrifuge Mikro 220 R     Hettrich (Tuttlingen, Germany) 
Digital Caliper                    Emil Lux GmbH & Co. KG (Wermelskirchen, 
                                          Germany) 
Gas Anesthesia  
System XGI-8                    Caliper Life Sciences GmbH (Rüsselsheim, 
                                          Germany) 
Grundig MC4541 shaver  Grundig GmbH (Nürnberg, Germany)  
Heating pad   Terra exotica (Alfeld, Germany) 
IVIS® spectrum Caliper Life Sciences GmbH (Rüsselsheim, 
Germany) 
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Megafuge 1.0 RS   Heraeus Holding GmbH (Hanau, Germany)  
Olympus CK30  
microscope                        Olympus Deutschland GmbH (Hamburg, 
Germany) 
Scale TE601   Sartorius AG (Göttingen, Germany)  
Scale PB160P  Sartorius AG (Göttingen, Germany) 
Infrared- lamp   Philips GmbH (Hamburg, Germany)   
Vi-Cell TM XR                    Beckmann Coulter GmbH (Krefeld, Germany) 
1.8 Software 
Microsoft Office 2016 Microsoft (Redmond, USA) 
Graph Pad Prism 7  GradPad Software, Inc. (San Diego, USA) 
Living Image 4.4  Caliper Life Sciences (Rüsselsheim, Germany) 
 
2. Mice 
2.1. Laboratory mouse strains 
All laboratory mice were bred for experimental use and kept in captivity 
since birth. For the in vivo experiments female mice were used only. Mice 
were purchased in an age between five to six weeks from Envigo or Charles 
River.  
2.1.1. BALB/c 
The BALB/cOlaHsd mice are inbred albino mice which were obtained from 
Envigo. They were born in the Netherlands. BALB/c mice have an intact 
innate and adaptive immune system. These gentle mice are often used in 
experiments concerning oncology, teratology and pharmacology [101]. 
They were also used as sentinel animals for health monitoring examinations 
in our animal facility. 
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2.1.2. C57BL/6 
The C57BL/6JOlaHsd strain is the most widely used inbred strain from 
Envigo. The breeding takes place in the Netherlands. This mouse strain has 
a completely intact immune system. They are often used in oncology 
research and as background for genetically modified mice models [101]. 
2.1.3. C57BL/6 albino 
The C57BL/6BrdCrHsd-Tyrc mice have the same genetic background as the 
C57BL/6 mice but with a mutation in the tyrosinase gene wherefore they are 
albino mice. They have an intact immune system. The mice were bred in 
France by Envigo. The advantage of this mouse strain in our animal 
experiments is the simple feasibility to image them without problems in the 
IVIS® spectrum [101]. 
2.1.4. Fox Chase SCID 
The CB17/Icr-Prkdcscid/IcrIcoCrl strain obtains mice which have a genetic 
autosomal recessive mutation. Therefore, they have a severe 
immunodeficiency affecting B and T lymphocytes, but they still have 
functional natural killer cells, macrophages, and granulocytes. Due to their 
immunodeficiency, a lot of human cancer cell lines can be monitored in 
these mice in vivo. Charles River breeds these mice in Germany [102]. 
2.1.5. NOD scid gamma (NSG) 
The JAXTM mouse strain NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ has a severe 
immunodeficiency concerning B cells, T cells and natural killer cells as well 
as cytokine signaling due to an IL2 receptor gamma chain deficiency. For 
this reason, the NSG mice are often used for xenograft models with 
hematopoietic stem cells and cancer stem cells. It is also possible to use 
them for patient-derived xenograft cell experiments. Charles River delivers 
these mice from the Jackson Laboratory in France to our animal facility 
[102]. 
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2.2. Housing 
All mice used for the in vivo experiments were kept in a special air-
conditioned room with a twelve hours day and night cycle. The mice were 
housed in individually ventilated cages (IVC, type II long, Tecniplast) with a 
maximal occupancy of five mice per cage and a minimal occupancy of two 
mice per cage. All over the time the mice had ad libitum access to 
autoclaved water and autoclaved food (complete feed for rat and mice-
maintenance, sniff®). The cages and the water were changed once a week. 
In terms of environmental enrichment every cage was equipped with litter, 
crinklets, nestlets, one mouse igloo, one mouse tunnel, a wire hanger, 
aspen bricks and one exercise wheel (Fast-Trac®).  
The health status of the animals was monitored according to the FELASA 
guidelines four times a year. During the work for this thesis all health 
monitoring reports were negative. Therefore, negative influence on the in 
vivo experiments caused by bacteria, virus or parasites can be excluded.  
All mice at least had one week to acclimatize to their new housing after the 
shipping before they were used for the in vivo experiments. During an 
experiment, the mice were controlled daily.  
All animal experiments were performed according to German legislation for 
the protection of animals and were approved by the government of Upper 
Bavaria (approval numbers 55.2-1-54-2532-107-13, 55.2-1-54-2532-22-
2016). 
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3. Methods 
3.1. Cell culture 
Murine breast adenocarcinoma cells (4T1-luc) stably expressing luciferase 
were cultivated in RPMI 1640 medium containing 10% FCS. Similarly, 4T1-
luc siTPC2 cells and 4T1-luc siNT cells (generated by Dr. Ong Nam Phuong 
Nguyen, LMU Munich) were cultivated in RPMI 1640 medium containing 
10% FCS. The patient-derived xenograft acute myeloid leukemia cells AML-
372 were cultured in DD medium, which was kindly provided by Prof. 
Dr. Irmela Jeremias. Rat hepatoma cell line McA-RH7777 (provided by PD 
Dr. Hans Zischka, Helmholtz Centre Munich), murine hepatocellular 
carcinoma cells expressing luciferase (Ril175-luc) (provided by Lars König, 
LMU Munich), Ril175-luc Cdk5 KO cells (generated by Maximilian Ardelt, 
LMU Munich), Ril175-luc TPC2 KO cells (generated by Martin Müller, LMU 
Munich), murine hepatocellular carcinoma cell line Hep55c-luc and all 
HUH7 cells (human hepatocellular carcinoma cell line) were cultivated in 
DMEM medium containing 10% FCS. HUH7 resi(+) cells, HUH7 resi(+)-luc 
cells, and HUH7 resi(-) cells were generated by Maximilian Ardelt and 
Martina Meßner (both LMU Munich). Through permanent treatment with 
sorafenib below their IC50 value the sorafenib resistant cell line HUH7 resi(+) 
was generated. After months of increasing the sorafenib dose, the HUH7 
resi(+) cells tolerate 10 µM sorafenib in DMEM. To receive HUH7 resi(-) 
cells, the HUH7 resi(+) cells were cultured without sorafenib for 72 hours.  
All cells were cultured under constant humidity at 37° C and with 5% CO2. 
In general, to use adherent cells (4T1-luc, Hep55c-luc, HUH7, Ril175-luc, 
McA-RH7777) for an in vivo experiment the first step was to remove the 
medium. Afterwards the cells were washed two times with PBS. Then the 
cells were incubated with trypsin/EDTA for 3 minutes at 37° C to detach 
them from the cell culture flask. To stop this reaction growth medium is 
added again into the flask. After counting the cells via Vi-Cell TM XR, the 
needed amount of them was taken out of the flask and centrifuged using the 
Megafuge 1.0 RS (1,000 rpm, 5 min, 20° C). In the end, the cell pellet was 
solved in PBS. In comparison, in case cells in suspension (AML-372) were 
used, the cells were counted via Vi-Cell TM XR without removing them from 
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medium. The needed amount of the solution was taken off and centrifuged 
(1,000 rpm, 5 min, 20° C). Afterwards the cells were resuspended in PBS. 
3.2. Animal experiments 
Laboratory mice were purchased from Envigo or Charles River at an age of 
five to six weeks and the experiments started with animals at an age of six 
to eight weeks. All mice acclimatized at least one week before entering an 
experiment. For subcutaneous, intraperitoneal, and intravenous injections 
1 ml syringes and 27 G needles were utilized. To carry out intravenous 
injections a forward or a backward restrainer was used depending on the 
cooperation and the size of the mice. For subcutaneous injections, the mice 
were shaved before cell injection. Inhalation anesthesia for 
bioluminescence imaging was performed with 2 to 3% isoflurane in oxygen. 
During the anesthesia, the cornea was prevented from drying out with 
ophthalmic ointment (Bepanthen® Augensalbe). For cardiac puncture, BD 
Micro-FineTM 0.3 ml were used. In the end of the animal experiments mice 
were sacrificed via cervical dislocation. When it was rational to keep the 
tumors, they were removed, photographed, and weighed. One part of them 
was frozen in liquid nitrogen and stored at - 80° C and the other part was 
fixed with 4% PFA, after three days transferred into 1% PFA, and three days 
later conserved in 70% ethanol and stored at 4° C. 
3.2.1. Bioluminescence measurement in living animals - 
IVIS® spectrum in vivo imaging system 
Bioluminescence measurements are based on an enzymatic reaction 
between luciferase tagged tumor cells and luciferin as its substrate. Under 
an ATP consuming reaction in the presence of oxygen luciferase catalyzes 
the reaction from luciferin into oxyluciferin. By returning from the excited 
state to the ground state oxyluciferin is emitting light [103]. This light can be 
detected by the IVIS® spectrum. With this sensitive way of optical imaging 
the total number of mice per group can be reduced because every single 
mouse can be imaged at different time points [104]. 6 mg luciferin sodium 
salt solved in 100 µl PBS were injected intraperitoneally in the mice before 
they were anesthetized. After the injection, the mice were put into a narcosis 
chamber flooded with 3% isoflurane in oxygen. The narcotized mice were 
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taken out of the narcosis chamber, got eye ointment applied to prevent their 
eyes from drying out, and were placed into the IVIS® spectrum. During the 
bioluminescence measurement, the mice are narcotized with 2% isoflurane 
in oxygen through a nose coin with gas anesthesia inlet and outlet ports. 
They were prevented from becoming hypothermic by laying on a hotplate 
(37° C). Mice were imaged in ventrodorsal position as standard and in 
dorsoventral or laterolateral position if there were specific indications. In 
every position four to eight readings were taken with intervals of one minute 
between each measurement.  To evaluate the signal, the region of interest 
(ROI) was defined. With the Living Image 4.4 software the bioluminescence 
signal within the ROI was calculated in photons/second/cm². The 
bioluminescence signal is indicated in total flux/area. Shown is one 
timepoint out of the sequence. In this thesis the IVIS® spectrum is used for 
longitudinal monitoring of tumors in living mice as well as for control 
measurements and end point measurements of single organs at the end of 
an experiment.  
 
Figure 14: IVIS® spectrum in vivo imaging system [105] 
3.2.2. Dose finding tests 
Dose finding tests were performed to find out an adequate dose of a 
compound for an animal experiment. By these dose finding tests the highest 
possible dosage of a compound that does not harm the mice or lead to any 
abnormalities shall be found. For the dose finding experiment the same 
mouse strain was used as for the main experiment. The compounds were 
solved in 5% DMSO, 10% solutol, and 85% PBS and were injected 
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intraperitoneally using 1 ml syringes and 27 G needles. If intravenous 
injections were indicated, the compound was just solved in PBS. Every 
mouse was injected with a volume of 100 µl at most once a day. The 
intervals and the duration of testing the compounds depended on the plans 
for the following main experiment. The tested dosages depended on results 
of in vitro concentrations and, if available, published data. As the dosages 
published in literature are not generally appropriable because of other 
mouse strains or other routes of administration, the dosage given in 
literature can sometimes just be seen as a hint. After injection, the mice 
were monitored directly and after thirty minutes, two hours, and twenty-four 
hours and after that daily. In some dose finding experiments the mice were 
observed for a few days after the last injection of the compound to see if 
there are decelerated reactions on the treatment. During these experiments, 
the mice were examined concerning their general condition, their behavior, 
their appearance, their breathing, body condition score and weight. They 
were especially monitored for toxic effects of the compounds such as 
cyanoses, anorexia, icterus or any signs of pain. The exact treatment plan 
for the compounds used in dose finding tests can be seen in Table 1.  
Table 1: Treatment plan for dose finding tests 
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3.2.3. Pharmacokinetic studies 
In the pharmacokinetic studies we had a look at the blood plasma 
concentration of compounds at different time points after the injection. After 
the compound was injected, the mice were set back to their cage. After the 
demanded time, the mice were euthanized via cervical dislocation. Then the 
thorax was opened and blood was taken via cardiac puncture. The blood 
was filled into 2 ml EDTA-blood tubes and centrifuged at 1,000 rpm for ten 
minutes. The blood plasma was analyzed by Dr. Christoph Müller and Anna 
Niedrig (LMU Munich, Germany) using HPLC. Details of the experimental 
conditions can be found in Table 2. 
Table 2: Conditions of pharmacokinetic studies 
 
3.2.4. Dissemination assays 
Dissemination assays were performed to evaluate the distribution of tumor 
cells after they were injected intravenously. As the cells were injected 
intravenously, the mice had to be restrained with a forward or a backward 
restrainer depending on their size and their cooperation on handling. The 
veins were dilated with an infrared lamp for about 15 seconds. Afterwards 
the tumor cells which were solved in 100 µl PBS were injected using 1 ml 
syringes and 27 G needles into the tail vein. As the cells are tagged with 
luciferase, it is possible to detect their bioluminescence signal afterwards in 
the IVIS® spectrum. For one thing, this assay can be used to evaluate the 
potential of compounds to reduce tumor dissemination. Therefore, the mice 
were treated with the compound before cell injection, not afterwards. For 
another thing, it is also possible to monitor tumor dissemination when the 
cells were pretreated or genetically modified before. So, it is not necessary 
to treat the mice before cell injection. In both cases the mice were imaged 
one or two times in the week after the cell injection. A third option to measure 
in a dissemination assay concerns tumor cell distribution in general. There 
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is the possibility to image the bioluminescence signal in short times after the 
tumor cell injection to evaluate the dissemination of the cells in the first hours 
in a living organism. Details for single dissemination experiments can be 
found in Table 3. 
 
 
Figure 15: Tumor dissemination model. Tumor cells were injected into 
the tail vein, pretreatment of the mice via intraperitoneal injections.  
 
Table 3: Conditions of dissemination experiments 
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3.2.5. Ectopic tumor models for the evaluation of tumor growth 
Ectopic tumor models were used to monitor the inhibiting effect of 
compounds on the growth of tumor cells or to evaluate the growth rate of 
subcutaneous tumors. Therefore, tumor cells were injected into the left flank 
of the mouse using 1 ml syringes and 27 G needles. Before cell injection 
the mice were shaved on the left lateral abdomen. After the cell injection, 
the tumor size was measured in three dimensions (L = length, longest side 
of the tumor, W = width, widest side of the tumor, and H = height, highest 
side of the tumor) using a digital caliper every two to three days. The tumor 
volume was calculated using the formula 1/6 x π x L x W x H. Another 
approach to measure the tumor load in ectopic tumor models was 
established for the first time in our lab during this thesis. Instead of just 
measuring the size of a subcutaneous tumor via a digital caliper, tumor cells 
were tagged with luciferase before the injection. Then it was possible to 
measure the bioluminescence signal of the subcutaneous tumors very 
precisely. These bioluminescence measurements were conducted biweekly 
using the IVIS® spectrum. In the end of the experiments, the tumors were 
resected, photographed, weighed, and measured. After that, one part was 
frozen at -80° C and the other part was conserved in 4% PFA. The detailed 
conditions for the implemented ectopic tumor models can be seen in Table 
4. 
 
 
Figure 16: Ectopic tumor model. Tumor cells were injected 
subcutaneously, treatment via intraperitoneal injection.  
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Table 4: Details for the conditions chosen for ectopic tumor models 
 
3.2.6. Patient derived xenograft cell model for monitoring leukemia 
In this patient derived xenograft (PDX) cell model human leukemia cells 
(AML-372), which were provided by Prof. Dr. Irmela Jeremias and Dr. Binje 
Vick (both Helmholtz Centre, Munich), were monitored in NOD scid gamma 
mice (NSGs). Therefore, 1x105 AML-372 cells were injected intravenously. 
As the AML-372 cells are tagged with luciferin, bioluminescence 
measurement in the IVIS® spectrum was possible to control the leukemic 
burden in the mice. 24 days after the first cell injection the mice received a 
second AML-372 cell injection with 1x105 due to a very reduced growing of 
the tumor cells after the first injection. The mice were imaged in the IVIS® 
spectrum once a week until the tumor signal reached at least 
1x108 total flux/area. When this signal was exceeded the treatment of the 
mice began and the tumor burden was measured twice a week via the IVIS® 
spectrum. The mice were divided into four groups, from which one group 
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served as control group, one group was treated with PS89 (solved in 5% 
DMSO, 10% solutol, and 85% PBS), one group was treated with liposomal 
daunorubicin (solved in glucose 5%), and the fourth group received a 
combination treatment with PS89 and liposomal daunorubicin. The detailed 
treatment plan can be seen in Table 5. With this PDX model the proliferation 
of leukemia cells can be observed in vivo under treatment with different 
compounds and the effects of their combination can be evaluated. 
Whenever a control injection was recommended, a solvent of 5% DMSO, 
10% solutol, and 85% PBS was used for the intraperitoneal injections and 
glucose 5% was used for the intravenous injections. 
 
Figure 17: Leukemia model. After intravenous cell injection leukemic 
tumor cells are detectable in the whole mouse body.  
 
Table 5: Classification of different groups in a PDX cell leukemia 
model 
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3.2.7. Orthotopic tumor model for evaluation of metastasis 
In this murine tumor model, the metastasis of liver cancer cells was 
observed. During a surgery liver cancer cells (Hep55c or Ril175-luc) were 
injected into the spleen. The narcosis of the mice consisted of 1 mg/kg 
medetomidine and 10 mg/kg midazolam. The antagonization consisted of 
0.5 mg/kg flumazenil and 2.5 mg/kg atipamezole. For pre- and 
postoperative analgesia 0.125 mg/kg buprenorphine was used. The mice 
received buprenorphine for altogether four days. After the mice reached 
Stage III in the Guedel`s classification, their skin was shaved and 
disinfected. Then the skin and the muscles of the left lateral abdomen were 
opened one centimeter in length. On the open abdomen, the spleen was 
pushed outside with slight pressure by a cotton swab containing PBS. Cells 
solved in 50 µl PBS were slowly injected into the spleen using a Hamilton 
syringe. In the following the injection site was compressed with a cotton 
swab containing 70% ethanol. The peritoneum, the muscles and the skin 
were sutured in two layers. The described surgery was mainly done by 
Laura Posselt (LMU Munich, Germany). Afterwards the metastasis 
formation in the liver was measured using bioluminescence detection in the 
IVIS® spectrum. In this orthotopic in vivo assay, the anti-metastatic effects 
of a compound can be observed. Therefore, the mice were only treated 
before the cell injection. The detailed conditions for these experiments can 
be seen in Table 6. 
 
Figure 18: Intrahepatic metastasis model. A) Cell injection into the 
spleen. B) Metastasis formation. Injection of a primary tumor into the spleen 
and metastasis formation in the liver. Figure created by Prof. Dr. Johanna 
Pachmayr (Paracelsus Medical University, Austria). 
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Table 6: Conditions of orthotopic tumor models for the evaluation of 
metastasis formation in C57BL/6-Tyr mice 
  
3.2.8. Statistical analysis 
Results are expressed as mean value ± S.E.M. if not indicated otherwise. 
Statistical analysis was performed with unpaired t-tests using GraphPad 
Prism 7. P-values < 0.05 were considered as significant.  
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III.  RESULTS 
1. Evaluation of murine dose finding tests  
Dose finding tests were performed to find out a well-tolerated dosage of our 
compounds. They were important to assure an uncomplicated procedure in 
following experiments. A detailed overview over the conditions gives 
Table 1 on page 27. 
1.1. Neocarzilin A  
Neocarzilin A was tested in three female BALB/c mice per group in dosages 
from 0.02 – 20 mg/kg via intraperitoneal injection. The compound was 
injected on three following days (from day 0 to day 3). The dosages 
0.02 mg/kg and 0.2 mg/kg were tested by Dr. Melanie Ulrich (LMU Munich, 
Germany). The mice which received 0.02 up to 10 mg/kg had a good 
general condition and did not show any abnormalities. The mice which 
received 20 mg/kg had a reduced general condition directly after the second 
and third injection and did not put full weight on their left leg after the 
injection for 30 minutes. Therefore, these three mice were euthanized after 
the last treatment. All groups were constant in their body weight when 
comparing the first and the last day of the experiment (Figure 19) and stayed 
on BCS 3. These results led to the decision to use neocarzilin A in a dosage 
of 10 mg/kg for the following dissemination experiment to avoid the negative 
side effects we have seen in the higher dosage. 
 
Figure 19: Body weight development over time. Weight of mice during 
the dose finding experiment with neocarzilin A injection on day 0, 1, and 2. 
Represented is the mean ± S.E.M. of three mice per group.  
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1.2. CA1 
CA1 was tested in three female SCID mice in the dosage of 100 mg/kg via 
intraperitoneal injection every second day. After the first injection on day 0 
the mice lost body weight but began to regain weight after day 2. After six 
injections in total and three days of observation after the last injection, the 
mean body weight was minimally higher (16.9 g) than at the beginning of 
the dose finding experiment (16.6 g) (Figure 20). Since the third CA1 
injection the mice showed an extremely active and stressed behavior for 20 
minutes after the treatment, but no typical signs of pain. Nevertheless, we 
decided to use 100 mg/kg CA1 for the ectopic tumor model, based on 
published data wherein CA1 treatment daily or twice a day in a dosage of 
100 mg/kg was tolerated by mice. To reduce stress for the mice we decided 
to reduce the treatment interval and to inject the mice only three times a 
week with 100 mg/kg CA1 in the ectopic tumor model.  
 
Figure 20: Body weight development over time. Weight of mice during 
the dose finding test with CA1 injections every second day. Represented is 
the mean ± S.E.M. of three mice per group.  
 
1.3. Dinaciclib 
Dinaciclib was tested in three female C57BL/6 mice per group in the 
dosages 10 mg/kg, 20 mg/kg, and 30 mg/kg via intraperitoneal injection. 
The mice received the injections on day 0, day 1, and day 2. During the 
three days of treatment the mice showed a good general condition without 
detectable abnormalities although the groups which received 20 mg/kg and 
30 mg/kg lost weight during the three days of treatment (Figure 21). The 
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mice in the 30 mg/kg group recovered weight in the days after the treatment 
and reached their weight of day 0 whereas the mice in the 10 mg/kg group 
had a constant weight during the whole experiment. On day 9 one mouse 
of the 10 mg/kg group had to be euthanized because of a swollen leg and 
exuding wound at the intraperitoneal injection site. The other two mice 
treated with 10 mg/kg dinaciclib were euthanized on day 10 without 
detectable abnormalities and a good general condition. Two of the mice 
which received 20 mg/kg dinaciclib had to be euthanized on day 4 due to a 
bad general condition. The third mouse of this group was found dead in 
cage on day 7. In the 30 mg/kg dinaciclib group one mouse was euthanized 
because of bad general condition and a swollen leg on day 7. On day 8 and 
9 the other two mice were euthanized because of swollen legs and exuding 
wounds at the intraperitoneal injection site. All abnormalities appeared 
suddenly and the mice were sacrificed immediately when they showed any 
wearing abnormalities. Due to the problems in the 20 mg/kg and the 
30 mg/kg group we decided to use 10 mg/kg dinaciclib for the metastasis 
model and the dissemination assay.  
 
Figure 21: Body weight development over time. Weight of mice during 
the dose finding experiment with dinaciclib injections on day 0, 1, and 2. 
Represented is the mean ± S.E.M. of three mice per group. 
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1.4. Sorafenib 
Sorafenib was tested in four SCID mice divided into two groups. One group 
received 20 mg/kg sorafenib, the other group received 30 mg/kg sorafenib 
for six injections in total. Injections took place every second day starting on 
day 0.  All four mice gained weight during the experiment but reacted with a 
low-grade weight loss on the injections the following day (Figure 22). The 
general condition during the whole experiment was good in both groups and 
no abnormalities were detectable. As the body weight development of 
mouse 1 and mouse 2 was better during the injections than in the other two 
mice, the consequence was to use 20 mg/kg sorafenib in the tumor growth 
model.  
 
Figure 22: Body weight development over time. A) Weight of mice during 
the dose finding experiment with sorafenib injection on day 0, 2, 4, 6, 8, and 
10. Each curve presents the body weight of one single mouse. B) Weight of 
mice during the dose finding experiment with sorafenib injection on day 0, 
2, 4, 6, 8, and 10. Represented is the mean ± S.E.M. of two mice per group. 
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1.5. Doxorubicin 
Doxorubicin was tested in six BALB/c mice divided into two groups. They 
were injected intravenously on day 0 with 1.5 mg/kg and 3 mg/kg 
doxorubicin, respectively. After the injection and for the following 48 hours 
of monitoring, the mice showed a good general condition without detectable 
abnormalities. Their body weight was nearly constant or even slightly 
increased (Figure 23). Therefore, we decided to use 3 mg/kg doxorubicin 
for further experiments. 
 
Figure 23: Body weight development over time. Weight of mice during 
the dose finding experiment with doxorubicin injection on day 0. 
Represented is the mean ± S.E.M. of three mice per group. 
 
1.6. Latrunculin B 
Latrunculin B was tested in three female BALB/c mice per group in dosages 
of 0.05 mg/kg, 0.1 mg/kg, and 0.5 mg/kg via singular intraperitoneal 
injection on day 0 in combination with 3 mg/kg doxorubicin injected 
intravenously 20 minutes after the latrunculin B injection. Injections with 
0.05 mg/kg and 0.1 mg/kg latrunculin B were tolerated well, the mice 
showed a physiological general condition. In both groups the mice slightly 
lost weight during the observation period of 24 and 48 hours, respectively 
(Figure 24). All three mice injected with 0.5 mg/kg latrunculin B showed a 
severely reduced general condition including paralysis of the extremities 15 
minutes after the injection, thus doxorubicin was not injected. These mice 
had to be euthanized immediately. Therefore 0.1 mg/kg latrunculin B 
combined with 3 mg/kg doxorubicin was used for further experiments.  
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Figure 24: Body weight development over time. Weight of mice during 
the dose finding experiment with latrunculin B and doxorubicin injection on 
day 0. Represented is the mean ± S.E.M. of three mice per group. 
 
1.7. Jasplakinolide 
Jasplakinolide was tested in three female BALB/c mice per group in 
dosages of 0.25 mg/kg, 0.5 mg/kg, and 1 mg/kg via intraperitoneal injection 
in combination with 3 mg/kg doxorubicin injected intravenously 20 minutes 
after the jasplakinolide injection. The compound was injected on day 0 
without further injections. All mice treated with 0.25 mg/kg and 0.5 mg/kg 
jasplakinolide tolerated the injections well and showed a good general 
condition during the whole dose finding experiment. The mice injected with 
1 mg/kg jasplakinolide also had no detectable abnormalities after the 
injection and during the first six hours after the treatment, but 24 hours after 
the injection one mouse was found dead in cage, whereas the other two 
mice showed a good general condition. The body weight of the mice which 
were treated with 0.25 mg/kg jasplakinolide increased slightly, whereas the 
body weight of the group treated with 0.5 mg/kg stayed equal and the group 
treated with 1 mg/kg jasplakinolide showed a slightly decreasing body 
weight (Figure 25). Therefore, we decided to use 0.5 mg/kg jasplakinolide 
combined with 3 mg/kg doxorubicin for further experiments. 
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Figure 25: Body weight development over time. Weight of mice during 
the dose finding experiment with jasplakinolide injection on day 0. 
Represented is the mean ± S.E.M. of three mice per group.  
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2. Examination of pharmacokinetic studies  
Knowledge of pharmacokinetic attributes is important to find the right 
dosage of a compound and to get an idea of its mode of action. Detailed 
experimental conditions can be seen in Table 2 on page 28. 
2.1. Evaluation of PS89 in pharmacokinetic studies 
Blood plasma concentrations of the compound PS89 were examined after 
intravenous and intraperitoneal injections. In the intravenous setup, the 
sample out of the pooled blood plasma taken directly after the injection 
contained 0.16 µg/µl PS89. Five and eight minutes after the injection 
0.018 µg/µl PS89 were detected. After ten minutes 0.077 µg/µl PS89 was 
found in the blood plasma. 15 minutes after the injection 0.004 µg/µl PS89 
were detected (Figure 26). In the intraperitoneal setup blood plasma 
concentrations were measured 15 minutes and 120 minutes after the 
injection. It was possible to detect 0.0023 µg/µl PS89 in the pooled blood 
plasma of four mice after 15 minutes. 120 minutes after the intraperitoneal 
injection PS89 was not detectable any more.  
 
Figure 26: Blood plasma concentration after intravenous injection. 
Blood was taken 0, 5, 8, 10, and 15 minutes after 10 mg/kg PS89 was 
injected. Every measured value represents a pooled blood plasma sample 
of two mice. Measurement was done by Dr. Christoph Müller and Anna 
Niedrig. 
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3. In vivo tumor models to evaluate tumor 
dissemination 
We conducted dissemination assays as a first step of in vivo 
characterization of new compounds, which showed promising effects on 
tumor cell migration and invasion in vitro. Hence, dissemination assays 
provide insights if a compound is able to influence tumor formation in vivo.   
Detailed experimental condition can be seen in Table 3 on page 29. 
3.1. Examination of dissemination of 4T1-luc cells 
Assays with bioluminescence measurements in the first hours after tumor 
cell injection were performed for the first time in our lab to implement a new 
imaging setup. In this new experimental setup, we focused on the 
procedures taking place short time after the intravenous cell injection. We 
wanted to detect a bioluminescence signal in the IVIS® spectrum already 
few hours after the cell injection. Therefore, we injected a significantly higher 
number of cells compared to established dissemination assays. In contrast 
to other dissemination assays, the mice were imaged at least once a day 
on consecutive days.                
The first assay was performed with five BALB/c mice, which were injected 
with 5x106 4T1-luc cells (murine breast adenocarcinoma cells). The 
bioluminescence measurements took place 3 hours, 6 hours, and 24 hours 
after the cell injection. Due to lung embolism two mice had to be euthanized 
directly after the cell injection. In the three remaining mice, a clear tumor 
signal was visible since the first measurement. Three hours after the 
injection, the mean bioluminescence signal was 2.5x108 total flux/area, then 
the signal decreased to 1.5x108 total flux/area 6 hours after the injection and 
increased to 6.4x108 total flux/area 24 hours after the cell injection (Figure 
28B). The general condition of the three remaining mice was reduced. They 
also showed reduction of weight between 4.5% and 24.4% within 24 hours 
(Figure 28A). 
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Figure 27: Bioluminescence imaging of 4T1-luc cells. Pictures of tumor 
burden in three BALB/c mice in ventrodorsal position 3, 6, and 24 hours 
after i.v. cell injection of 5x106 4T1-luc cells. 
 
 
Figure 28: Body weight development and tumor growth. A) Body weight 
development. Decrease of mice` weight for 24 hours. Each curve represents 
one single mouse. B) Tumor burden in the lungs. The tumor burden was 
measured 3, 6, and 24 hours after i.v. cell injection. Each curve represents 
the tumor burden in total flux/area of one single mouse. 
 
In a second approach, two BALB/ c mice were injected with 1x106 4T1-luc 
cells intravenously and two BALB/c mice were injected with 2x106 4T1-luc 
cells. In all mice, the tumor signal was most obvious in the lung, additionally 
one mouse which received 2x106 4T1-luc cells showed a tumor signal in the 
spleen after three hours (Figure 29). In the group which was injected with 
the higher number of cells the mean bioluminescence signal was 
7.0x107 total flux/area 3 hours after the injection, 7.4x108 total flux/area 
after 6 hours, 1.0x108 total flux/area after 24 hours and 
3.5x108 total flux/area after 48 hours. In the group which received the lower 
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number of cells, the mean bioluminescence signal was 
2.6x107 total flux/area after 3 hours, 1.8x107 total flux/area after 6 hours, 
2.8x107 total flux/area after 24 hours, and 8.1x107 total flux/area after 
48 hours (Figure 30B). The general condition of the mice was good and 
without detectable abnormalities. The body weight increased low-grade 
during the 48 hours of the experiment (Figure 30A). The number of 
bioluminescence measurements as well as the injected number of cells was 
limited by the general condition of the mice. As the reduced general 
condition and the lung embolism in the group injected with 5x106 4T1-luc 
cells was not tolerable, we decided to use 2x106 4T1-luc cells for further 
experiments.  
 
Figure 29: Bioluminescence imaging of 4T1-luc cells. Pictures of tumor 
burden in four BALB/c mice in ventrodorsal position 3, 6, 24, and 48 hours 
after i.v. cell injection of 1x106 and 2x106 4T1-luc cells, respectively. 
 
III. Results     46 
 
Figure 30: Body weight development and tumor growth. A) 
Development of mice` weight for 2 days. Each curve represents the mean 
± S.E.M. of two mice per group. B) Tumor burden in the lungs. The tumor 
burden was measured 3, 6, 24, and 48 hours after i.v. cell injection. Each 
curve represents the mean tumor burden ± S.E.M. of two mice per group. 
 
3.2. Effects of neocarzilin A on dissemination of 4T1-luc cells  
The compound neocarzilin A was tested in a dissemination model with the 
dosage of 10 mg/kg. 16 BALB/c mice were divided into two groups, one 
control group and one neocarzilin A treated group. The mice were 
pretreated with 10 mg/kg neocarzilin A or just solvent 48 h, 24 h, and 0.5 h 
before the injection of 1x105 murine breast adenocarcinoma 4T1-luc cells 
on day 0 (detailed conditions can be seen in Table 3 on page 29). The 
general condition of the mice was good during the experiment and no 
abnormalities were detectable. Body weight in both groups increased during 
the experiment (Figure 31). Bioluminescence signal was detectable in the 
lung of seven mice in the control group and in all mice in the neocarzilin A 
treated group. On day 5 and on day 8 the signal was higher in the control 
group in comparison to the treated group. The control group reached in 
mean 2.3x108 total flux/area on day 5 and 1.9x109 total flux/area on day 8, 
whereas the neocarzilin A treated group reached in mean 8.9x107 total 
flux/area on day 5 and 1.2x109 total flux/area on day 8 (Figure 32). Thus, 
neocarzilin A was able to reduce dissemination of murine breast cancer 
cells into the lung. 
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Figure 31: Body weight development. Weight of mice during the 
dissemination experiment. Represented is the mean ± S.E.M. of eight mice 
per group. 
 
 
Figure 32: Bioluminescence imaging in BALB/c mice. A) 
Bioluminescence imaging on day 5. Measurement in ventrodorsal position 
five days after the i.v. injection of 1x105 4T1-luc cells. B) Bioluminescence 
imaging on day 8. Measurement in ventrodorsal position eight days after the 
i.v. injection of 1x105 4T1-luc cells. Represented is the mean ± S.E.M. of 
seven mice in the control group and eight mice in the neocarzilin A treated 
group.   
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3.3. Examination of Ril175-luc cell dissemination 
The dissemination of murine liver cancer cells Ril175-luc was tested in six 
C57BL/6-Tyr mice, divided into two groups. One group received 
1x105 Ril175-luc cells, the other group received 2x105 Ril75-luc cells on 
day 0. The bioluminescence measurements took place on day 3 and day 5. 
During this experiment, the general condition of all mice was unimpeded 
and the body weight stayed almost constant. On day 3 and on day 5 
bioluminescence signals were detectable in the lungs of all six mice (Figure 
33). The mean bioluminescence signal in the group injected with the lower 
number of Ril175-luc cells was 5.2x105 total flux/area on day 3 and 
2.6x106 total flux/area on day 5. The mean bioluminescence signal in the 
group injected with the higher number of Ril175-luc cells was 3.0x106 
total flux/area on day 3 and 8.0x106 total flux/area on day 5 (Figure 34B). 
Thus, we could establish an imaging setup of murine liver cancer cells 
Ril175-luc with the IVIS® spectrum for the first time in our lab. For further 
dissemination experiments we decided to inject 2x105 Ril175-luc cells into 
the tail vein.  
 
Figure 33: Bioluminescence imaging of Ril175-luc cells. The 
bioluminescence signal of both groups is shown on day 3 and on day 5 after 
i.v. injection of 1x105 respectively 2x105 Ril175-luc cells. The mice were 
imaged in ventrodorsal position. 
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Figure 34: Body weight development and tumor growth. A) Body weight 
development over time. Weight of mice during the dissemination 
experiment. Represented is the mean ± S.E.M. of three mice per group. B) 
Bioluminescence signal of Ril175-luc cells. Measurements were performed 
on day 3 and on day 5. Represented is the mean ± S.E.M. of three mice per 
group. 
 
3.4. Effects of Cdk5 inhibition on Ril175-luc cell dissemination 
In the first part of this experiment the Cdk5 inhibitor dinaciclib was tested in 
a dissemination assay with 20 C57BL/6 albino mice, divided into two 
groups. Mice were pretreated with 10 mg/kg dinaciclib 48 h, 24 h, and 0.5 h 
before the intravenous injection of 2x105 murine liver cancer cells Ril175-
luc. Bioluminescence imaging was performed on day 3 after the tumor cell 
injection. During the experiment, the general condition of both groups was 
good and without detectable abnormalities in behavior. Both groups started 
the experiment with nearly equal body weight on day -2 (19.0 g in the mean 
in the control group and 18.8 g in the mean in the dinaciclib treated group), 
the control group was able to gain weight during the experiment (day 3: 
19.4 g in the mean), whereas the dinaciclib treated group lost weight (day 3: 
18.3 g in the mean) (Figure 36A). On day 3 the bioluminescence signal was 
significantly lower in the dinaciclib treated group (3.6x106 total flux/area) 
than in the control group (2.0x106 total flux/area) (Figure 36B). Thus, 
10 mg/kg dinaciclib was sufficient to reduce tumor dissemination of murine 
liver cancer cells in vivo. 
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Figure 35: Bioluminescence imaging in C57BL/6 albino mice. 
Bioluminescence imaging on day 3. Measurement in ventrodorsal position 
three days after the i.v. injection of 2x105 Ril175-luc cells.  
 
 
Figure 36: Effects of dinaciclib on tumor dissemination. A) Body weight 
development. Weight of mice during the dissemination experiment. 
Represented is the mean ± S.E.M. of ten mice per group. B) Tumor signal 
on day 3 after cell injection. Represented is the mean ± S.E.M. of ten mice 
per group. Significance was calculated by unpaired t-test (* p < 0.05). 
 
In the second part of the experiment dissemination of murine liver cancer 
cells Ril175-luc with Cdk5 KO was tested. 10 mice per group were injected 
intravenously with 2x105 Ril175-luc Cdk5 KO cells or Ril175-luc wt cells.  
The mouse weight during this experiment was nearly constant (Figure 39A), 
the general condition of the mice was without detectable abnormalities. 
Three days after the cell injection the cell dissemination was impaired by 
Cdk5 knockout (1.2x106 total flux/area) compared to wildtype cells 
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(4.8x106 total flux/area) (Figure 39B). Thus, this set of data shows that the 
influence of Cdk5 on dissemination of murine liver cancer cells could be 
proven. 
 
Figure 37: Cdk5 KO Ril175-luc cells. Western Blot showing the protein 
levels of Cdk5 in RiL175-luc wild-type cells and RiL175-luc Cdk5 KO cells 
generated via the CRISPR/Cas method by Maximilian Ardelt. 
 
Figure 38: Bioluminescence imaging in C57BL/6 albino mice. 
Bioluminescence imaging on day 3. Measurement in ventrodorsal position 
three days after the i.v. injection of 2x105 Ril175-luc Cdk5 KO cells or 
Ril175-luc wt cells as control. 
 
Figure 39: Effects of Cdk5 KO on tumor dissemination. A) Body weight 
development. Weight of mice during the dissemination experiment. 
Represented is the mean ± S.E.M. of ten mice per group. B) Tumor signal 
on day 3 after cell injection. Represented is the mean ± S.E.M. of ten mice 
per group. Significance was calculated by unpaired t-test (* p < 0.05). 
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3.5. Effects of TPC2 on tumor cell dissemination  
The first part of this experimental setup consisted of a dissemination assay 
with Ned-19 pretreated cells. Therefore, murine breast adenocarcinoma 
cells 4T1-luc were pretreated with 150 µmol/L Ned-19 for 24 hours. Each of 
the seven BALB/c mice received 1x105 4T1-luc cells via intravenous 
injection on day 0. As control group seven BALB/c mice received 1x105 4T1-
luc cells pretreated with DMSO for 24 hours. The mice were imaged on day 
5. During the experiment, the general condition of the mice was good and 
their body weight was nearly constant (Figure 41A). The bioluminescence 
signal on day 5 was significantly lower in the Ned-19 group (2.2x106 total 
flux/area) than in the control group (7.0x106 total flux/area) (Figure 41B). 
Thus, Ned-19 pretreatment was able to reduce tumor dissemination in 
murine breast cancer cells significantly. 
 
Figure 40: Bioluminescence imaging in BALB/c mice. Measurements in 
ventrodorsal position on day 5 after i.v. injection of 1x105 4T1-luc cells 
pretreated with 150 µmol/L Ned-19 or DMSO as control.  
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Figure 41: Effects of Ned-19. A) Body weight development over time. 
Weight of mice during the dissemination experiment. Represented is the 
mean ± S.E.M. of seven mice per group. B) Bioluminescence signal of 4T1-
luc cells. Represented is the mean ± S.E.M. of seven mice per group. 
Significance was calculated by unpaired t-test (** p < 0.01). Statistical 
analysis was done by Dr. Ong Nam Phuong Nguyen [55]. 
 
In the second dissemination assay 1x105 TPC2-silenced 4T1-luc cells 
(siTPC2) were intravenously injected in eight BALB/c mice. As control eight 
BALB/c mice received control transfected 4T1-luc cells (siNT). The mice 
were imaged on day 5 after the cell injection. All mice showed a good 
general condition and an increasing body weight during the experiment 
(Figure 43A). The bioluminescence signal of tumor cells in the lung in the 
siTPC2 group (6.2x106 total flux/area) was significantly lower than in the 
siNT group (2.4x107 total flux/area) (Figure 43B). Hence, silencing TPC2 
reduced dissemination of murine breast cancer cells significantly.  
 
Figure 42: Bioluminescence imaging in BALB/c mice on day 5. 
Measurements in ventrodorsal position on day 5 after i.v. injection of 1x105 
siTPC2 4T1-luc cells or siNT 4T1-luc cells as control. 
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Figure 43: Effects of silencing TPC2. A) Body weight development over 
time. Weight of mice during the dissemination experiment. Represented is 
the mean ± S.E.M. of eight mice per group. B) Bioluminescence 
measurement of 4T1-luc cells. Represented is the mean ± S.E.M. of eight 
mice per group. Significance was calculated by unpaired t-test (** p < 0.01). 
 
The following dissemination experiment was performed with murine liver 
cancer Ril175-luc TPC2 KO cells. One group of ten C57BL/6-Tyr mice was 
injected with 2x105 Ril175-luc cells without genetical manipulation and 
served as control group, whereas ten other mice were injected with 
2x105 Ril175-luc TPC2 KO cells. During the experiment, the mice gained 
body weight and showed a good general condition (Figure 45A). On day 3 
after the cell injection the bioluminescence signal of the TPC2 KO tumors 
was significantly lower (2.3x106 total flux/area) compared to the control 
group (1.0x107 total flux/area) (Figure 45B). Accordingly, it could be shown 
that TPC2 is a potential target to reduce tumor dissemination in vivo.  
 
Figure 44: Bioluminescence imaging in C57BL/6 albino mice. 
Measurements in ventrodorsal position on day 3 after i.v. injection of 
2x105 Ril175-luc TPC2 KO cells or 2x105 Ril175-luc cells as control.  
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Figure 45: Effects of TPC2 KO. A) Body weight development over time. 
Weight of mice during the dissemination experiment. Represented is the 
mean ± S.E.M. of ten mice per group. B) Bioluminescence signal of Ril175-
luc cells. Shown are the tumor signals of both groups in ventrodorsal 
position. Significance was calculated by unpaired t-test (*** p < 0.001). 
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4. Examination of murine ectopic tumor models  
In ectopic tumor models the tumor growth of murine breast adenocarcinoma 
cells 4T1-luc, rat hepatoma cells McA-RH7777, and human hepatocellular 
carcinoma cells HUH7 was evaluated. In this model, it is possible to 
characterize the growth of different cell lines, find a suitable mouse strain 
for further experiments as well as to examine the influence of different 
compounds on subcutaneous tumor growth. Detailed information on the 
experimental conditions can be seen in Table 4 on page 31. 
4.1. Preliminary growth experiment with 4T1-luc cells 
In this preliminary growth experiment BALB/c mice were subcutaneously 
injected with 1x106 murine breast adenocarcinoma cells 4T1-luc to 
determine the tumor growth rate for further experiments. Three days after 
the cell injection in three out of four mice subcutaneous tumors were visible. 
On day 6 after the cell injection all mice developed subcutaneous tumors 
with a mean tumor volume of 70 mm3. In the end of the experiment on day 
9, the mean tumor volume amounted 194 mm3 (Figure 46B). During the 
whole experiment the general condition of the mice was good, they lost body 
weight after the cell injection but in the end gained weight compared to their 
initial weight (Figure 46A). Thus, 4T1-luc cells are suitable for breast cancer 
growth models. 
 
Figure 46: Results of preliminary growth experiment. A) Body weight 
development over time. Weight of mice during the experiment. Represented 
is the mean ± S.E.M. of four mice per group. B) Tumor growth over time. 
Represented is the mean ± S.E.M. of four mice per group. 
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4.2. Preliminary growth experiment with McA-RH7777 cells 
In this growth experiment we wanted to find a suitable mouse strain for 
experiments with the rat hepatoma cell line McA-RH7777. As this cell line 
was used for the first time in an in vivo mouse model in our lab, no mouse 
strain was established. Therefore, it was of interest, if McA-RH7777 cells 
were able to form subcutaneous tumors in SCID mice. Four SCID mice were 
injected with 2x106 McA-RH7777 cells on day 0. On day 7 tumors were 
visible in two of four mice. On day 9 tumors were visible in all four mice with 
a mean tumor volume of 49 mm3. On the last day of the experiment the 
mean tumor volume was 145 mm3 (Figure 47B) and the tumor weight was 
between 0.05 mg and 0.15 mg after resection (Figure 47C). The general 
condition of all four SCID mice was good during the whole experiment with 
a constant body weight (Figure 47A). Therefore, we demonstrated that McA-
RH7777 cells grow subcutaneously in SCID mice and can be used for 
further tumor growth models.   
 
Figure 47: Results of growth experiment. A) Body weight development 
over time. Weight of mice during the experiment. Represented is the mean 
± S.E.M. of four mice per group. B) Tumor growth over time. Represented 
is the mean ± S.E.M. of four mice per group. C) Tumor weight after resection 
on day 11. D) Pictures of tumors after resection.  
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4.3. Evaluation of HUH7 cells in a murine ectopic tumor model 
The aim of the first part of this in vivo experiment was to find out, if all of the 
in vitro tested human hepatocellular carcinoma HUH7 cell lines are able to 
build subcutaneous tumors in SCID mice. In vitro, the proliferation of HUH7 
wildtype (wt) and HUH7 sorafenib resistant cell lines HUH7 resi(+) and 
HUH7 resi(-) differ significantly. Whereas HUH7 wt and HUH7 resi(+) cells 
proliferated similarly in vitro, the doubling time of HUH7 resi(-) cells was less 
than half compared with the other HUH7 cells (unpublished data).  In 
addition, HUH7 wildtype cells show a significantly higher average volume 
than HUH7 sorafenib resistant cells (unpublished data).  To test their growth 
in vivo, 3x106 HUH7 wt cells, HUH7 resi(-) cells, and HUH7 resi(+) cells 
were injected subcutaneously in three mice per group. The groups which 
were injected with HUH7 wt cells and the HUH7 resi(-) cells were treated 
with solvent. Two groups were injected with HUH7 resi(+) cells. One of this 
groups was treated with solvent the other group was treated with 20 mg/kg 
sorafenib i.p. three times a week (detailed conditions can be seen in Table 
4 on page 31). During the experiment, the general condition of the mice was 
unimpeded and their body weight was nearly constant until day 6 after the 
cell injection. Since day 6 the whole HUH7 resi(-) group showed a loss of 
body weight and on day 11 a bad general condition, so that they had to be 
euthanized. The other groups showed constant body weight development 
until the end of the experiment on day 15, except for the HUH7 resi(+) group 
treated with solvent (Figure 48A). They had a reduced body weight on day 
11 but anyhow a good general condition. Except for one mouse in the 
HUH7 wt cell group and one mouse in the HUH7 resi(+) cell group treated 
with solvent, in all mice tumor growth was visible. The HUH7 wt cells 
showed the biggest tumor growth in vivo with a tumor volume of 284 mm3 
in the mean on day 15 (Figure 48B). The HUH7 resi(+) group had a mean 
tumor volume of 55 mm3 on day 15, the HUH7 resi(+) group which received 
sorafenib treatment had a mean tumor volume of 25 mm3 on day 15.  The 
HUH7   resi(-) group was euthanized on day 11 with a mean tumor size of 
21 mm3 (Figure 48C). In this preliminary experiment we could prove that all 
HUH7 cell lines are able to form subcutaneous tumors in vivo. Moreover, it 
was possible to show a slightly reduced tumor growth in HUH7 resi(+) cells 
treated with sorafenib in vivo compared to HUH7 resi(+) without further 
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treatment in vivo. Further, HUH7 wt cells formed tumors with the biggest 
volume after 15 days.  
 
Figure 48: Results of the preliminary tumor growth experiment. A) 
Body weight development over time. Weight of mice during the experiment. 
Represented is the mean ± S.E.M. of three mice per group. B) Tumor growth 
over time. Tumor volume of different HUH7 cell lines treated just with solvent 
and HUH7 resi(+) cells treated with 10 mg/kg sorafenib three times a week. 
Each curve represents the mean ± S.E.M. of two or three mice per group. 
C) Tumor growth over time. Tumor volume of different HUH7 sorafenib 
resistant cell lines with and without sorafenib treatment. Each curve 
represents the mean ± S.E.M. of two or three mice per group. 
 
In the second part of the ectopic tumor model, tumor growth was tested in 
HUH7 wt cells and HUH7 resi(+) cells with and without sorafenib treatment. 
Therefore 36 mice were divided into four groups. 16 mice received HUH7 
wt cells and eight of them were treated with 20 mg/kg sorafenib every 
second day. 20 mice received HUH7 resi(+) cells and ten of them were 
treated with 20 mg/kg sorafenib every second day. During the whole 
experiment the body weight in all groups was constant. The general 
condition of the mice was without detectable abnormalities. On day 15 the 
HUH7 wt control cells showed the highest mean tumor volume of 533 mm3. 
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On the same day the HUH7 wt cells which were treated with sorafenib 
showed a mean tumor volume of 134 mm3. The HUH7 resi(+) control cells 
had a mean tumor volume of 228 mm3 on day 15, and a mean tumor volume 
of 313 mm3 on day 16. The HUH7 resi(+) cells with sorafenib treatment 
showed a mean tumor volume of 89 mm3 on day 15, and a mean tumor 
volume of 178 mm3 on day 16 (Figure 50B). After tumor resection (day 15 
or day 16), the HUH7 wt control tumors had a mean weight of 0.32 g, the 
HUH7 wt tumors under sorafenib treatment had a mean weight of 0.07 g, 
the HUH7 resi(+) control tumors had a mean weight of 0.22 g, and the HUH7 
resi(+) tumors under sorafenib treatment had a mean weight of 0.13 g 
(Figure 50C). Moreover, we observed an invasive tumor growth in both 
HUH7 sorafenib resistant cell lines. Relating to tumor weight after resection 
we could see a reduction of tumor volume in HUH7 wt tumors as well as in 
HUH7 resi(+) tumors under sorafenib treatment. Interestingly, in all mice, 
HUH7 wt tumors appeared deep red and well vascularized whereas all 
HUH7 resi(+) tumors appeared pale and exsanguinated (Figure 49) 
suggesting a reduced vascularization and thereby less blood supply in these 
tumors.  
 
Figure 49: Solid HUH7 tumors after resection. After euthanasia the skin 
was opened and the subcutaneous tumors were resected, weighted and 
photographed. Represented are three representative tumors of each group. 
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Figure 50: Results of HUH7 tumor growth experiment. A) Body weight 
development over time. Weight of mice during the experiment. Represented 
is the mean ± S.E.M. of eight respectively ten mice per group. B) Tumor 
growth over time. Tumor volume of HUH7 wt and HUH7 resi(+) cells with 
and without 20 mg/kg sorafenib treatment every second day. Each curve 
represents the mean ± S.E.M. of eight or ten mice per group. C) Tumor 
weight after resection. S.c. tumors were resected after euthanizing the mice 
and scaled. Represented is the mean ± S.E.M. of eight or ten mice per 
group. 
 
In the third part of this project, HUH7 resi(+)-luc cells were injected 
subcutaneously to investigate the influence of treatment with the 
experimental natural compound CA1 on tumor growth. Therefore, 10 SCID 
mice were divided into two groups. One group just received treatment with 
solvent and served as control. The other group was intraperitoneally treated 
with 100 mg/kg CA1 three times a week. In contrast to the other ectopic 
tumor models, we changed our experimental setup and imaged the 
subcutaneous tumors twice a week using the IVIS® spectrum additionally to 
caliper measurements. The general condition of the mice was good during 
the experiment, except for a reduced general condition of the CA1 treated 
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mice for 15 minutes after the intraperitoneal injection. Bioluminescence 
signal was detectable already three days after the cell injection (Figure 
51A). On day 3, both groups showed a nearly equal bioluminescence signal 
of 3.2x107 total flux/area in the control group and 1.4x107 total flux/area in 
the CA1 treated group. On day 7 and on day 10 the bioluminescence signal 
in the control group was 3.9x109 total flux/area and 9.7x109 total flux/area, 
respectively. In the CA1 treated group the bioluminescence signal was 
3.0x108 total flux/area on day 7 and 1.9x109 total flux/area on day 10 (Figure 
52B). Subcutaneous tumors were visible and measurable with the digital 
caliper since day 8. The tumor volume measured with the digital caliper was 
also higher in the control group compared to the CA1 treated group (Figure 
52C). In the same way, tumor weight after resection was significantly higher 
in the control group compared to the CA1 treated group (Figure 52D). 
Therefore, we implemented a functional new imaging setup for HUH7-luc 
cells, which allows bioluminescence measurements in a short interval after 
the cell injection. Moreover, the natural compound CA1 significantly reduced 
subcutaneous tumor growth of HUH7 resi(+)-luc cells.  
 
Figure 51: Subcutaneous tumor growth of HUH7 resi(+)-luc cells. A) 
Bioluminescence imaging in SCID mice. Measurements in dorsoventral 
position on days 3, 7, and 10 after s.c. injection of 3x106 HUH7 resi(+)-luc 
cells. B) Pictures of tumors after resection on day 10.  
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Figure 52: Results of HUH7 resi(+)-luc tumor growth experiment. A) 
Body weight development over time. Weight of mice during the experiment. 
Represented is the mean ± S.E.M. of five mice per group. B) 
Bioluminescence signal of s.c. HUH7 resi(+)-luc tumors treated with 
100 mg/kg CA1 or solvent as control. Each curve represents the mean ± 
S.E.M. of five mice per group.  C) Tumor growth over time measured with a 
digital caliper. Tumor volume of different HUH7 resi(+)-luc cells treated with 
100 mg/kg CA1 or solvent as control three times a week. Each curve 
represents the mean ± S.E.M. of five mice per group. D) Tumor weight after 
resection on day 10. Significance was calculated by unpaired t-test 
(* p < 0.05, ** p < 0.01, *** p < 0.001). 
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5. Evaluation of a PDX cell leukemia model for AML-372  
To evaluate the effects of PS89 and liposomal daunorubicin (DaunoXome®) 
on progression of acute myeloid leukemia, a mouse model with patient 
derived xenograft leukemia cells (AML-372) was performed. Details 
concerning the exact experimental setup can be seen in Table 5 on page 
32.  Before starting the treatment, the mouse body weight increased in all 
groups and the mice showed a physiological general condition without any 
abnormalities. During the treatment period, the mice in the control group 
and the PS89 treated group had a nearly constant body weight, whereas 
the mice in the daunorubicin group and the combination group showed 
reduction of weight (Figure 53). The duration of treatment differed between 
the four groups. The control mice and the mice which received PS89 were 
treated 13 to 20 days without abnormalities. The mice treated with liposomal 
daunorubicin were treated 8 to 13 days and had to be euthanized due to 
bad general condition in the majority of cases. In the same way the mice in 
the combination group were treated 8 to 15 days and were euthanized 
because of a decreasing general condition. Bioluminescence signal of the 
tumor burden was visible in the IVIS® spectrum in the femora, the humeri, 
the pelvis (in parts of the mice) and the sternum (in parts of the mice). In 
some mice the bioluminescence signal was diffuse at the end of the 
treatment period (Figure 55A). On day 12 of the treatment, the PS89 group 
showed a bioluminescence signal of 1.5x109 total flux/area, the control 
group 1.3x109 total flux/area, the combination group 1.2x109 total flux/area, 
and the daunorubicin treated group 7.7x108 total flux/area. On day 14 of the 
treatment, the daunorubicin treated group showed a bioluminescence signal 
of 1.0x109 total flux/area, the PS89 group showed a bioluminescence signal 
of 9.4x109 total flux/area (n=1), and the combination group 7.4x109 total 
flux/area (n=1). The other mice of the daunorubicin and the combination 
group had to be euthanized before day 14 due to a decreasing general 
condition mainly caused by daunorubicin treatment. On day 17 the control 
group showed a bioluminescence signal of 8.0x109 total flux/area and the 
PS89 treated group showed a bioluminescence signal of 2.4x109 total 
flux/area (Figure 54 and Figure 55B). Unfortunately, comparison of leukemic 
tumor load between the different experimental groups was not possible after 
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an adequate treatment period. Furthermore, these data revealed the 
problematic side effects of multiple daunorubicin treatment in mice.  
 
Figure 53: Body weight development over time.  A) Weight of mice 
during the whole experimental period (day 0 – day 75). Represented is the 
mean ± SEM per group. B) Weight of mice during the treatment period. 
Represented is the mean ± S.E.M. per group. 
 
 
Figure 54: Results of bioluminescence imaging. Each curve represents 
the mean tumor load ± S.E.M. of nine or ten NSG mice per group. The 
treatment begins on day 0, when a bioluminescence signal of 1x108 is 
reached. Analysis was done by Dr. Fabian Koczian. 
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Figure 55: Bioluminescence imaging of AML-372 cells. A) Pictures of 
tumor burden in 40 NSG mice at the beginning of the treatment and prior to 
sacrifice. Days of treatment above or below the pictures. Pictures are taken 
in ventrodorsal position. B) Results of bioluminescence imaging. 10 mice 
per group were imaged once a week before treatment and twice a week 
during the treatment period. Treatment started when the bioluminescence 
signal reached 1x108 total flux/area. Every curve represents the tumor load 
of one single NSG mouse. ROIs were drawn as whole-body ROIs. 
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6. Tumor metastasis evaluated in an orthotopic liver 
cancer model 
To examine metastasis formation, we established an intrahepatic 
metastasis formation assay as described above for the first time in our lab. 
In a preliminary experiment two different murine liver cancer cell lines, 
Hep55c-luc and Ril175-luc (with two different numbers of cells), were tested. 
In every group one or two mice were treated with 10 mg/kg dinaciclib three 
times before cell injection (detailed conditions can be seen in Table 6 on 
page 34). All mice tolerated the surgery well and recovered completely 
within 24 hours afterwards. The surgical wound healed up without any 
complications. The body weight increased during the pretreatment (day -2 
to day 0) but decreased after the surgery (day 0 to day 2). Two days after 
the surgery the body weight increased again until the end of the experiment 
(Figure 56). In the bioluminescence measurements tumor signals in the 
spleen and in the liver were detectable (Figure 57). Mice were imaged in 
ventrodorsal and dorsoventral position. As the Ril175-luc cells showed a 
reliable growth in vivo and dinaciclib was able to reduce tumor cell migration 
in this preliminary experiment, we decided to inject 1x106 Ril175-luc cells in 
the main experiment.         
 
Figure 56: Body weight development. Weight of mice during the whole 
experimental period (day 0 – day 9). Represented is the mean ± S.E.M. of 
three or four mice per group. 
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Figure 57: Bioluminescence imaging of preliminary intrahepatic 
metastasis model with 1x106 Ril175-luc cells injected into the spleen. 
A) Pictures of tumor cell migration in mice, taken on days 3, 6, and 9 in 
dorsoventral imaging position. B) Bioluminescence signals in total flux/area 
of spleen and liver on day 3, 6, and 9. 
In the main experiment, inhibition of metastasis from spleen to liver was 
examined using 1x106 murine liver cancer cells Ril175-luc and pretreatment 
of mice with 10 mg/kg dinaciclib three times before cell injection. Ten mice 
served as control group and ten mice were pretreated with dinaciclib. The 
general condition during the pretreatment was without detectable 
abnormalities. After the surgery, the dinaciclib pretreated mice needed one 
day longer to recover than the control mice (Figure 58). Four mice of the 
dinaciclib treated group also opened their skin suture the day after the 
surgery, so that they had to be narcotized and the wound needed to be 
stitched again. In the dorsoventral imaging two split signals were detectable. 
The signal on the left side of the mouse was considered as spleen, the 
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signal on the right side was considered as liver. With this way of interpreting 
the signals, the bioluminescence signal on day 3 after the cell injection was 
higher in the spleen than in the liver in both groups. On day 6 the tumor 
signal of the dinaciclib treated group in the spleen was slightly higher 
(3.6x108 total flux/area) than in the liver (3.0x108 total flux/area), whereas 
the tumor signals in the control group were approximately equal in both 
organs (tumor signal in the spleen 2.5x108 total flux/area, tumor signal in 
the liver 2.3x108 total flux/area). This leads to the result, that tumor cell 
metastasis from spleen to liver could be reduced in comparison to the 
control group. However, unfortunately the ex vivo imaging of the solid 
organs showed a higher mean tumor signal in the liver than in the spleen 
on day 7 in both groups (Figure 59). Thus, we concluded that the 
combination of dinaciclib treatment, narcosis and surgery weakened the 
mice. Based on the ex vivo imaging, a reduction of intrahepatic metastasis 
formation by dinaciclib treatment was not detectable seven days after the 
cell injection. 
 
Figure 58: Body weight development. Weight of mice during the whole 
experimental period (day 0 – day 7). Represented is the mean ± S.E.M. of 
ten mice per group.   
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A                    B 
 
Figure 59: Bioluminescence signal measurement. A) Images in 
dorsoventral position of mice on day 3 and day 6, or imaging of the solid 
organs on day 7 after injection of 1x106 Ril175-luc cells into the spleen. B) 
Evaluation of tumor signals in the intrahepatic metastasis model on day 3, 
6, and 7. Bioluminescence signals for spleen and liver shown in 
total flux/area. Represented is the mean ± S.E.M. per group.  
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IV. DISCUSSION 
1. Neocarzilin A as a potential natural compound to 
impede tumor cell dissemination 
Neocarzilin A showed promising in vitro effects against different cancer cell 
lines in our lab (data not published yet). Tested in vivo in a dissemination 
assay, neocarzilin A was able to reduce tumor dissemination of the murine 
breast cancer cell line 4T1-luc. In tumorigenesis, cancer cells have to 
detach from the primary tumor to reach the bloodstream. Consequently, 
they are transported to well circulated organs like the lung or the brain and 
are able to form metastases in these organs. Relating to solid tumors, these 
metastases are the cause of more than 90% of all cancer related deaths 
[106]. Tumor dissemination assays are simplified experiments to evaluate 
the behavior of tumor cells after they reach the bloodstream. In a 
dissemination assay the part of detachment and reaching the blood 
circulation is imitated by the intravenous injection of tumor cells. After 
getting into the lung, tumor cells attach there and begin to proliferate. 
Therefore, it is important to do bioluminescence imaging in a preferably 
short interval after the cell injection, to minimize the influence of tumor 
proliferation and to gain insights into the inhibiting effects on cell 
dissemination. In case of neocarzilin A it would be an interesting option to 
implement bioluminescence imaging already in shorter time after the cell 
injection to evaluate the effects on tumor cell dissemination less influenced 
by tumor cell proliferation or apoptosis. For further research, investigation 
of effects on tumor growth would also be of interest. As 10 mg/kg 
neocarzilin A were well tolerated during multiple injections a long-term 
treatment with neocarzilin A would also be feasible.  
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2. Two-pore channel inhibition as a novel strategy to 
reduce tumor cell dissemination 
One team in our lab is investigating the roles of the endolysosomal system 
in development and treatment of cancer. The endolysosmal system of a cell 
plays a central role as cellular recycling center as well as central regulator 
of tumor growth and metastasis formation [107]. Furthermore, lysosomes 
are important for drug resistance in cancer cells and the autophagy-
lysosome pathway [108]. In a recent review by Grimm et al. it is shown that 
there is a multitude of links between cancer and lysosomal function, but the 
exact mechanism how lysosomes influence tumorigenesis and cancer 
progression is still unclear [109]. Two-pore channels are endolysosomal 
membrane proteins with essential roles in endolysosomal trafficking and the 
autophagy-lysosome pathway. Moreover, they are part of the superfamily of 
voltage-gated ion channels. Two-pore channels exist in two subtypes, of 
which TPC1 is predominantly expressed on early endosomal membranes, 
whereas TPC2 is mainly found in lysosomal membranes [110]. We were 
able to show that pharmacological inhibition by Ned-19 as well as silencing 
TPC2 with siRNA reduced dissemination of murine breast cancer cells in 
vivo [55]. Moreover, loss of TPC2 function in murine liver cancer cells with 
TPC2 knock-out diminished tumor dissemination significantly. For future 
investigations, the influence of TPC2 on tumor growth in vivo would be of 
interest. Moreover, newly developed natural compounds, which have the 
same promising target as the experimental compound Ned-19, will be tested 
on their potential to inhibit tumor cell dissemination and tumor growth in vivo. 
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3. Cdk5 inhibition as a new approach against liver 
cancer 
Cdk5 is a member of the cyclin-dependent kinase family, which are 
serine/threonine kinases playing an important role in the neuronal system, 
i.e. in the central nervous system as well as in axon guidance and synaptic 
function. Cdk5 contributes to neurodegenerative diseases like Alzheimer`s 
disease or amyotrophic lateral sclerosis [111]. In addition, Cdk5 turned out 
to have importance in non-neuronal tissues, especially in cancer cells [112-
114]. Inhibition of Cdk5 is also a promising target in the therapy of 
hepatocellular carcinoma [115]. Recent findings in our lab showed that Cdk5 
inhibition reduced HCC cell migration in vitro (data submitted).  In a tumor 
dissemination experiment we were able to show a reduced dissemination of 
murine liver cancer cells Ril175-luc by pharmacologic inhibition of Cdk5 via 
dinaciclib treatment in vivo. In this experiment the Cdk5 inhibitor dinaciclib 
was injected three times intraperitoneally in a dose of 10 mg/kg into the 
mice, because of impairing side effects with higher dosages of dinaciclib 
observed in dose finding tests. Equally Cdk5 knockdown by the 
CRISPR/Cas9 system was able to reduce dissemination of Ril175-luc cells 
in vivo. Thus, inhibition of Cdk5 might be a promising tool in HCC therapy. 
Moreover, as dinaciclib is already clinically approved, it might be a treatment 
option also for HCC. These dissemination models represent a simple 
method to monitor effects on tumor cells in vivo. A more realistic approach 
to investigate liver cancer is represented by our intrahepatic metastasis 
model. Conducting this experiment for the first time in our lab, we were able 
to explore tumor cell migration from the spleen to the liver by 
bioluminescence imaging. Unfortunately, this approach led to two problems 
in the experimental setup. On the one hand the combination of dinaciclib 
treatment and burden of the surgery weakened the mice. Consequently, 
more postoperative problems appeared in the dinaciclib treated group. On 
the other hand, we had to recognize the risk that bioluminescence signals 
of spleen and liver might overlap and impede a correct evaluation of the 
tumor signals. Therefore, there is the need of imaging the solid organs as a 
control measurement in the end of the experiment. To overcome the 
problem of an overlapping primary tumor in the spleen and metastasis in 
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the liver, Rajendran et al. described a split-spleen approach, where one part 
of the spleen that includes the primary tumor is resected ten minutes after 
the cell injection. The residual part of the spleen is able to fulfill immune 
protective properties, but will not impair the possibility to appropriate the 
bioluminescence signal to the corresponding organ [116]. In future 
experiments it would be of interest if Cdk5 knockout in murine liver cancer 
cells could reduce the cell migration from spleen to liver in an orthotopic liver 
cancer model.  
4. Sorafenib resistance in liver cancer cells evaluated 
in murine tumor models 
One major field of research in our lab focuses on hepatocellular carcinoma 
(HCC). Different general challenges of chemotherapy are represented by 
treatment problems of HCC. Mostly diagnosed in advanced stage, sorafenib 
is the only approved treatment option [117]. Besides wearing side effects as 
hand-foot syndrome, diarrhea and hypertension, HCC shows acquired 
sorafenib resistance and rebound growth phenomena after sorafenib 
withdrawal [79, 118]. Moreover, patient`s survival benefit of less than three 
months with a median overall survival of 10.7 months compared to 7.9 
months in the placebo group is still poor [118]. Therefore, one part of this 
thesis was the implementation of suitable mouse models for HCC and the 
evaluation of new treatment options.  We showed that 20 mg/kg sorafenib 
administered every two days is sufficient to reduce subcutaneous growth of 
HUH7 wildtype tumors in SCID mice. Moreover, we described a phenotypic 
totally unequal tumor growth of different HUH7 cells in vivo. Whereas HUH7 
wildtype tumors grew encapsulated and subcutaneously relocatable, HUH7 
resistant cells showed an extremely invasive growth into deeper muscle 
layers. After tumor resection HUH7 wildtype tumors appeared well 
vascularized, whereas the resistant cell lines formed exsanguinous tumors. 
These findings led us to the presumption that vascularization might be 
altered in sorafenib resistant HUH7 cells. A reduced vascularization would 
on the one hand lead to a possibly reduced availability of chemotherapeutic 
drugs in these tumors, on the other hand the tumor volume measured via a 
caliper might be underestimated compared to HUH7 wildtype tumors with a 
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higher density of vasculature. In future experiments, differences in 
angiogenesis of HUH7 cell lines will be examined. Due to the very invasive 
tumor growth of HUH7 resistant cells, tumor measurement via a caliper was 
vague. Moreover, the different cell size of HUH7 wildtype and HUH7 
sorafenib resistant cells could not be considered in these measurements. 
Therefore, we investigated a new experimental setup in which HUH7 
luciferase tagged cells were injected subcutaneously in order to build 
tumors. Thereby bioluminescence measurement of the tumor signal was 
feasible. Thus, evaluation of tumor growth was more precise, examiner 
independent, and comparison of tumor growth was possible in short times 
after the cell injection. In this experimental setup we were also able to show 
that the experimental natural compound CA1 reduced tumor growth of 
HUH7 sorafenib resistant cells in vivo. 
5. Patient-derived xenograft cells in a mouse model for 
acute myeloid leukemia 
In this part of the thesis we implemented an in vivo model for acute myeloid 
leukemia in our lab. Therefore, we worked with patient-derived xenograft 
(PDX) cells. In contrast to tumor cell lines, which often show altered 
functional characteristics due to their longtime cultivation, PDX cells are an 
option more closely related to the clinics [20]. As PDX cells showed a 
reliable tumor growth in NSG mice, these severely immunocompromised 
mice were used in this project. Due to their immunodeficiency, strict barriers 
and aseptic handling of the mice was important during the whole experiment 
[119]. In our leukemia model we had to deal with an insufficient tumor growth 
after the first intravenous cell injection. Therefore, we had to inject tumor 
cells for a second time, which also led to an inhomogeneous tumor growth. 
Bioluminescence signal was detectable in the hematopoietic bones 
primarily in the femora, followed by humeri and in parts of the mice also the 
sternum and the pelvis. Moreover complicating, mice treated with the 
anthracycline DaunoXome® did not tolerate more than three intravenous 
injections. As anthracyclines in general are related to cardiotoxic effects 
[120, 121], the treatment period of mice treated with DaunoXome® or a 
combination consisting of DaunoXome® and our compound PS89 was 
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limited to approximately ten days. Thus, we were not able to compare the 
tumor load between all groups after a longer treatment period. We could 
show that intraperitoneal injection of PS89 did not harm the mice for a longer 
period of time. Moreover, PS89 was detectable in the blood plasma 
15 minutes after intraperitoneal injection. For further experiments, different 
changes in the experimental setups might be possible. Based on in vitro 
data it would be a promising approach to combine PS89 with the 
chemotherapeutic agent etoposide, as there are no such negative side 
effects known as for anthracyclines. Furthermore, a clinically more relevant 
setup would consist in waiting for a very high tumor load, comparable with 
human patients at the timepoint of being diagnosed with acute myeloid 
leukemia. Then a short treatment period should start, with just one 
anthracycline treatment in large dose, combined with PS89 treatment. In our 
pharmacokinetic study, PS89 was not detectable any more 15 minutes after 
intravenous injection and 120 minutes after intraperitoneal injection. As we 
were only able to detect PS89 without further modification, potentially 
effective metabolites of PS89 were unconsidered in these measurements. 
For further investigation on PS89 it would be of interest, if effective 
metabolites of PS89 exist and could be detectable in the blood plasma of 
the mice. With these insights PS89 treatment could be planned more 
specifically.  
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V. SUMMARY 
Cancer is one of the biggest health problems in our days. Due to growth and 
aging of the human population as well as multiple, omnipresent risk factors 
the number of cancer cases and cancer related deaths is still increasing. As 
current cancer survival rates are not satisfying and available treatment 
options have to deal with wearing side effects, there is necessity for novel 
therapeutic options and improvement of established therapies. Therefore, 
our lab is investigating the anti-cancer potential of natural and synthetic 
compounds to find out new chances to fight cancer.     
In this project, compounds with promising in vitro findings were tested in 
murine tumor models to elucidate their potential in vivo. The aim of this 
thesis was the in vivo evaluation of auspicious experimental compounds in 
murine tumor models.                       
For a detailed in vivo characterization of our experimental compounds, they 
were tested in different experimental setups. We started with dose finding 
tests to figure out well tolerable dosages for in vivo treatments and 
pharmacokinetic studies to characterize compounds in more detail. Within 
this thesis we found adequate in vivo dosages for our compounds and their 
adjunction with approved drugs.                 
Concerning novel experimental approaches, it was part of this thesis to 
implement new experimental setups. Therefore, preliminary subcutaneous 
growth experiments with murine breast cancer cells 4T1-luc and rat 
hepatoma cells McA-RH7777 were conducted. Moreover, different 
modifications in the setup of dissemination assays were made, such as 
bioluminescence imaging of the murine liver cancer cell line Ril175-luc and 
imaging in short intervals after the cell injection, to examine essential 
procedures in the first hours after cell injection.              
In dissemination assays we showed that the natural compound 
neocarzilin A reduced tumor cell dissemination of murine breast cancer cells 
4T1-luc with a dosage of 10 mg/kg. Further, we showed that 
pharmacological inhibition of the two-pore channel TPC2 by Ned-19 or 
silencing TPC2 reduced tumor cell dissemination of 4T1-luc cells. 
Furthermore, both pharmacological inhibition by 10 mg/kg dinaciclib and 
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knockout of the cyclin dependent kinase Cdk5 via the CRISPR/Cas method 
reduced tumor cell dissemination of murine liver cancer cells Ril175-luc. To 
examine the influence of the Cdk5 inhibitor dinaciclib on metastasis 
formation, an intrahepatic metastasis model was conducted for the first time 
in our lab. Unfortunately, due to the wearing combination of dinaciclib 
treatment and surgery as well as problems by correlating the 
bioluminescence signal to the correct organ during the experiment, we were 
not able to show a reduction in metastasis formation under dinaciclib 
treatment.                              
In ectopic tumor models we focused on the investigation of hepatocellular 
carcinoma using different human HUH7 cell lines. Besides pharmacological 
inhibition of HUH7 wildtype tumor growth by 20 mg/kg sorafenib, we showed 
interesting differences in the phenotype of HUH7 wildtype and HUH7 
sorafenib resistant tumors. Whereas HUH7 wildtype tumors grew 
subcutaneously relocatable and well vascularized, HUH7 sorafenib 
resistant tumors grew invasive and less vascularized. Moreover, we 
implemented a new bioluminescence imaging setup for subcutaneous 
HUH7 tumors using the IVIS® spectrum. Therefore, we were able to show 
that the experimental natural compound CA1 reduced subcutaneous tumor 
growth of HUH7 sorafenib resistant cells.        
Within a leukemia project with patient derived xenograft (PDX) cells AML-
372 we conducted an in vivo model for acute myeloid leukemia. With our 
experimental compound PS89 we tried to improve daunorubicin treatment, 
which is an approved treatment option for acute myeloid leukemia in 
humans. Unfortunately, due to less tolerance of daunorubicin treatment in 
mice, we were not able to show a positive effect of combination of PS89 and 
daunorubicin in vivo.                  
In conclusion, this thesis elucidated the anti-cancer potential of new natural 
and synthetic compounds and established murine tumor models for further 
investigations on the antitumoral activity of promising compounds. 
 
 
VI. Zusammenfassung      79 
VI. ZUSAMMENFASSUNG 
Murine in vivo Tumormodelle zur Erforschung des anticancerogenen 
Potentials von Naturstoffen und synthetischen Compounds 
Krebserkrankungen stellen eines der größten Gesundheitsprobleme 
unserer Zeit dar. Aufgrund des Bevölkerungswachstums und einer immer 
älter werdenden Gesellschaft, sowie einer Vielzahl omnipräsenter 
Risikofaktoren steigt die Anzahl der Krebserkrankungen und der damit 
verbundenen Todesfälle weiter an. Da momentane Überlebensraten nicht 
zufriedenstellend sind und verfügbare Behandlungsoptionen mit oftmals 
belastenden Nebenwirkungen zu kämpfen haben, besteht ein großer 
Bedarf an neuen Behandlungsmöglichkeiten und an Verbesserungen für 
etablierte Therapien. Daher erforscht unser Labor das anticancerogene 
Potential von Naturstoffen und synthetischen Wirkstoffen, um neue 
Möglichkeiten im Kampf gegen Krebserkrankungen zu finden.           
In diesem Projekt werden Wirkstoffe mit vielversprechenden in vitro 
Ergebnissen in murinen Tumormodellen getestet, um ihr Potential in vivo 
aufzuklären. Das Ziel dieser Arbeit war die in vivo Evaluation von 
vielversprechenden experimentellen Compounds in murinen 
Tumormodellen.              
Für eine detaillierte in vivo Charakterisierung wurden unsere 
experimentellen Compounds in verschiedenen Versuchen getestet. Zu 
Beginn standen Dosisfindungstests, um eine gut tolerierte Dosierung für in 
vivo Behandlungen herauszufinden. Die Pharmakokinetik wurde 
untersucht, um Wirkstoffe noch genauer charakterisieren zu können. Im 
Rahmen dieser Arbeit konnten wir für unsere Compounds und für 
Kombinationstherapien mit zugelassenen Medikamenten adäquate 
Dosierungen finden.                  
In Bezug auf neue experimentelle Herangehensweisen war es Teil dieser 
Arbeit einen neuen Versuchsaufbau für verschiedene Experimente zu 
verwirklichen. Es wurden Vorversuche zum subkutanen Tumorwachstum 
mit der murinen Mammakarzinomzelllinie 4T1-luc sowie mit der 
Rattenhepatomzelllinie McA-RH7777 durchgeführt.  Des Weiteren wurden 
verschiedene Änderungen im Versuchsaufbau der Disseminationsversuche 
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durchgeführt. Es wurde die Biolumineszenzmessung der murinen 
Leberkrebszelllinie Ril175-luc etabliert, sowie ein Versuchsaufbau zur 
Messung der Biolumineszenz in kurzen Zeitintervallen nach der 
Zellinjektion entwickelt, um essentielle Vorgänge in den ersten Stunden 
nach der Tumorzellinjektion untersuchen zu können.               
In Disseminationsversuchen konnten wir zeigen, dass der Naturstoff 
Neocarzilin A mit einer Dosierung von 10 mg/kg die Tumorzelldissemination 
der murinen Mammakarzinomzellen 4T1-luc reduziert. Des Weiteren 
konnten wir zeigen, dass sowohl pharmakologische Inhibierung durch Ned-
19 sowie Silencing des „two-pore“ Kanals TPC2 die Dissemination von 4T1-
luc Zellen reduziert. Überdies hinaus reduziert sowohl die 
pharmakologische Inhibierung durch 10 mg/kg Dinaciclib als auch der 
Knock-out der cyklinabhängigen Kinase Cdk5 mittels der CRISPR/Cas 
Methode die Tumorzelldissemination von murinen Leberkarzinomzellen 
Ril175-luc. Um den Einfluss des Cdk5 Inhibitors Dinaciclib auf die 
Metastasenbildung zu untersuchen, führten wir im Rahmen dieser Arbeit 
zum ersten Mal in unserem Labor ein intrahepatisches 
Metastasierungsmodel durch. Aufgrund der belastenden Kombination aus 
Behandlung mit Dinaciclib und Operation, sowie Problemen bei der 
korrekten Zuordnung des Biolumineszenzsignals zum jeweiligen Organ 
während des Experiments, war es leider nicht möglich eine Reduktion der 
Metastasierung durch Dinaciclib zu zeigen.                   
In ektopischen Tumormodellen fokussierten wir uns auf die Erforschung des 
hepatozellulären Karzinoms, indem wir verschiedene humane HUH7 
Zelllinien verwendeten. Neben einer pharmakologischen Inhibierung des 
Wachstums von HUH7 Wildtyptumoren durch 20 mg/kg Sorafenib, konnten 
wir interessante Unterschiede im Phänotyp zwischen HUH7 
Wildtyptumoren und HUH7 Tumoren mit Sorafenibresistenz feststellen. 
Während HUH7 Wildtyptumore subkutan verschieblich und gut 
vaskularisiert wuchsen, zeigten HUH7 Tumore mit Sorafenibresistenz ein 
invasives und scheinbar weniger gut vaskularisiertes Wachstum. Zudem 
erstellten und realisierten wir einen neuen Versuchsaufbau, um die 
Biolumineszenz von subkutanen HUH7 Tumoren mittels des IVIS® 
spectrum zu messen. Hierbei war es uns möglich zu zeigen, dass der 
experimentelle Naturstoff CA1 das subkutane Wachstum von HUH7 
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Tumoren mit Sorafenibresistenz reduziert.             
Im Rahmen eines Leukämieprojektes mit den Patientenxenograftzellen 
AML-372 führten wir ein in vivo Model zur akuten myeloischen Leukämie 
durch. Mit unserem experimentellen Compound PS89 versuchten wir eine 
Behandlung mit Daunorubicin, welche für die akute myeloide Leukämie eine 
zugelassene Behandlungsmethode darstellt, zu verbessern. Die 
Behandlung mit Daunorubicin wurde von den Mäusen schlecht toleriert, 
wodurch wir leider keinen positiven Effekt durch die Kombination von PS89 
mit Daunorubicin in vivo zeigen konnten.            
Zusammenfassend zeigt diese Arbeit das anticancerogene Potential von 
Naturstoffen und synthetischen Compounds auf und etabliert murine 
Tumormodelle für die weitere Forschung an der antitumoralen Aktivität 
vielversprechender Wirkstoffe.  
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